CA2274319C - Methods and compositions for polypeptide engineering - Google Patents
Methods and compositions for polypeptide engineering Download PDFInfo
- Publication number
- CA2274319C CA2274319C CA2274319A CA2274319A CA2274319C CA 2274319 C CA2274319 C CA 2274319C CA 2274319 A CA2274319 A CA 2274319A CA 2274319 A CA2274319 A CA 2274319A CA 2274319 C CA2274319 C CA 2274319C
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- substrate molecules
- substrate
- fragments
- molecules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 283
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 28
- 229920001184 polypeptide Polymers 0.000 title claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 412
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 227
- 230000006798 recombination Effects 0.000 claims abstract description 142
- 238000005215 recombination Methods 0.000 claims abstract description 142
- 150000007523 nucleic acids Chemical class 0.000 claims description 393
- 239000000758 substrate Substances 0.000 claims description 263
- 102000039446 nucleic acids Human genes 0.000 claims description 262
- 108020004707 nucleic acids Proteins 0.000 claims description 262
- 108020004414 DNA Proteins 0.000 claims description 166
- 238000012216 screening Methods 0.000 claims description 75
- 108091034117 Oligonucleotide Proteins 0.000 claims description 67
- 238000002703 mutagenesis Methods 0.000 claims description 48
- 231100000350 mutagenesis Toxicity 0.000 claims description 48
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 47
- 239000013598 vector Substances 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 44
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 36
- 108010047761 Interferon-alpha Proteins 0.000 claims description 30
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 102000006992 Interferon-alpha Human genes 0.000 claims description 22
- 230000029087 digestion Effects 0.000 claims description 19
- 108091008146 restriction endonucleases Proteins 0.000 claims description 19
- 238000000338 in vitro Methods 0.000 claims description 16
- 229940035893 uracil Drugs 0.000 claims description 13
- 102000003960 Ligases Human genes 0.000 claims description 12
- 108090000364 Ligases Proteins 0.000 claims description 12
- 238000000137 annealing Methods 0.000 claims description 10
- 230000000295 complement effect Effects 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 9
- 230000000593 degrading effect Effects 0.000 claims description 7
- 108091008053 gene clusters Proteins 0.000 claims description 7
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 6
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 6
- 238000006062 fragmentation reaction Methods 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 238000013467 fragmentation Methods 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 238000010008 shearing Methods 0.000 claims description 4
- 238000000527 sonication Methods 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims 6
- 230000006862 enzymatic digestion Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 241
- 235000018102 proteins Nutrition 0.000 description 199
- 239000013612 plasmid Substances 0.000 description 109
- 230000001976 improved effect Effects 0.000 description 101
- 230000000694 effects Effects 0.000 description 87
- 239000000047 product Substances 0.000 description 87
- 230000014509 gene expression Effects 0.000 description 77
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 58
- 230000035772 mutation Effects 0.000 description 52
- 108020003175 receptors Proteins 0.000 description 51
- 102000005962 receptors Human genes 0.000 description 50
- 241000700605 Viruses Species 0.000 description 46
- 108010050904 Interferons Proteins 0.000 description 43
- 108091005804 Peptidases Proteins 0.000 description 41
- 239000003446 ligand Substances 0.000 description 39
- 102000035195 Peptidases Human genes 0.000 description 37
- 239000013615 primer Substances 0.000 description 37
- 102000014150 Interferons Human genes 0.000 description 36
- 239000004365 Protease Substances 0.000 description 36
- 230000006872 improvement Effects 0.000 description 36
- 241000282414 Homo sapiens Species 0.000 description 31
- 230000027455 binding Effects 0.000 description 31
- 230000008569 process Effects 0.000 description 31
- 108020004705 Codon Proteins 0.000 description 29
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 27
- 229940079322 interferon Drugs 0.000 description 24
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 23
- 230000006870 function Effects 0.000 description 23
- 235000019419 proteases Nutrition 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 229940088598 enzyme Drugs 0.000 description 22
- 108700008625 Reporter Genes Proteins 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000004520 electroporation Methods 0.000 description 21
- 108020001507 fusion proteins Proteins 0.000 description 21
- 235000013339 cereals Nutrition 0.000 description 20
- 102000037865 fusion proteins Human genes 0.000 description 20
- 241000588724 Escherichia coli Species 0.000 description 19
- 238000002823 phage display Methods 0.000 description 18
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 17
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 17
- 108060001084 Luciferase Proteins 0.000 description 17
- 238000012163 sequencing technique Methods 0.000 description 17
- 108700024394 Exon Proteins 0.000 description 16
- 239000005089 Luciferase Substances 0.000 description 16
- 230000004927 fusion Effects 0.000 description 16
- 108020004511 Recombinant DNA Proteins 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 230000003321 amplification Effects 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 230000010076 replication Effects 0.000 description 14
- 102000052603 Chaperonins Human genes 0.000 description 13
- 102000053602 DNA Human genes 0.000 description 13
- 241000724791 Filamentous phage Species 0.000 description 13
- 108091092195 Intron Proteins 0.000 description 13
- 108010021466 Mutant Proteins Proteins 0.000 description 13
- 102000008300 Mutant Proteins Human genes 0.000 description 13
- 239000000539 dimer Substances 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 12
- 210000004602 germ cell Anatomy 0.000 description 12
- 229940047124 interferons Drugs 0.000 description 12
- 239000003471 mutagenic agent Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 230000019491 signal transduction Effects 0.000 description 12
- 102100039556 Galectin-4 Human genes 0.000 description 11
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 11
- -1 KCI Chemical compound 0.000 description 11
- 108020004682 Single-Stranded DNA Proteins 0.000 description 11
- 150000001413 amino acids Chemical group 0.000 description 11
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 11
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 11
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 238000010369 molecular cloning Methods 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 230000003248 secreting effect Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 102000004506 Blood Proteins Human genes 0.000 description 10
- 108010017384 Blood Proteins Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 108010006785 Taq Polymerase Proteins 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 230000000840 anti-viral effect Effects 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 239000013600 plasmid vector Substances 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 239000003016 pheromone Substances 0.000 description 9
- 108010022997 phosphonoacetaldehyde hydrolase Proteins 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 101000688206 Bos taurus Intestinal-type alkaline phosphatase Proteins 0.000 description 8
- 101710104123 Deacetoxycephalosporin C synthase Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 229930195708 Penicillin V Natural products 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 229940056367 penicillin v Drugs 0.000 description 8
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 8
- 230000001902 propagating effect Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 239000013603 viral vector Substances 0.000 description 8
- 108700010070 Codon Usage Proteins 0.000 description 7
- 101710128836 Large T antigen Proteins 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 239000003599 detergent Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 238000005457 optimization Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 6
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 6
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 6
- 102100039064 Interleukin-3 Human genes 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000009395 breeding Methods 0.000 description 6
- 230000001488 breeding effect Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000003362 replicative effect Effects 0.000 description 6
- 238000002741 site-directed mutagenesis Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 102100031780 Endonuclease Human genes 0.000 description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 108090000787 Subtilisin Proteins 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000009824 affinity maturation Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 239000006151 minimal media Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000004091 panning Methods 0.000 description 5
- 229930001119 polyketide Natural products 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 210000001938 protoplast Anatomy 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229910052721 tungsten Inorganic materials 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- CBWCNKVANCTCAD-UHFFFAOYSA-N (4-nitrophenyl)phosphonic acid Chemical class OP(O)(=O)C1=CC=C([N+]([O-])=O)C=C1 CBWCNKVANCTCAD-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 101100064718 Borrelia bavariensis (strain ATCC BAA-2496 / DSM 23469 / PBi) fusA1 gene Proteins 0.000 description 4
- 101100209555 Caenorhabditis elegans vha-17 gene Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 101150009006 HIS3 gene Proteins 0.000 description 4
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 4
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 4
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 4
- 229930010555 Inosine Natural products 0.000 description 4
- 108700005090 Lethal Genes Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 230000003305 autocrine Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000012219 cassette mutagenesis Methods 0.000 description 4
- 101150091913 cefE gene Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000012203 high throughput assay Methods 0.000 description 4
- 229960003786 inosine Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 231100000219 mutagenic Toxicity 0.000 description 4
- 230000003505 mutagenic effect Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 238000013492 plasmid preparation Methods 0.000 description 4
- 101150055096 polA gene Proteins 0.000 description 4
- 150000003881 polyketide derivatives Chemical class 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 230000010474 transient expression Effects 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 101100185881 Clostridium tetani (strain Massachusetts / E88) mutS2 gene Proteins 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 102000034353 G alpha subunit Human genes 0.000 description 3
- 108091006099 G alpha subunit Proteins 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 241001124207 Luciola mingrelica Species 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010034133 Pathogen resistance Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 108010019653 Pwo polymerase Proteins 0.000 description 3
- 102100038803 Somatotropin Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- NNQIJOYQWYKBOW-JWKOBGCHSA-N deacetoxycephalosporin C Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@@H]12 NNQIJOYQWYKBOW-JWKOBGCHSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 101150117187 glmS gene Proteins 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003262 industrial enzyme Substances 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 101150013854 mutS gene Proteins 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 108700010839 phage proteins Proteins 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 210000002729 polyribosome Anatomy 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 101150079601 recA gene Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000011218 segmentation Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 2
- 102100040796 Glycoprotein hormones alpha chain Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 2
- 101001038874 Homo sapiens Glycoprotein hormones alpha chain Proteins 0.000 description 2
- 101001061518 Homo sapiens RNA-binding protein FUS Proteins 0.000 description 2
- 101000659267 Homo sapiens Tumor suppressor candidate 2 Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000000646 Interleukin-3 Human genes 0.000 description 2
- 108010054278 Lac Repressors Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000003792 Metallothionein Human genes 0.000 description 2
- 108090000157 Metallothionein Proteins 0.000 description 2
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000010645 MutS Proteins Human genes 0.000 description 2
- 108010038272 MutS Proteins Proteins 0.000 description 2
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 2
- OUXCBXHYDBLCDA-UHFFFAOYSA-N OP(=O)OC1=CC=C([N+]([O-])=O)C=C1 Chemical class OP(=O)OC1=CC=C([N+]([O-])=O)C=C1 OUXCBXHYDBLCDA-UHFFFAOYSA-N 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100028469 RNA-binding protein FUS Human genes 0.000 description 2
- 101100064044 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001655322 Streptomycetales Species 0.000 description 2
- 206010042566 Superinfection Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 238000002832 anti-viral assay Methods 0.000 description 2
- 238000007845 assembly PCR Methods 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- XJMXIWNOKIEIMX-UHFFFAOYSA-N bromo chloro 1h-indol-2-yl phosphate Chemical compound C1=CC=C2NC(OP(=O)(OBr)OCl)=CC2=C1 XJMXIWNOKIEIMX-UHFFFAOYSA-N 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 108010047295 complement receptors Proteins 0.000 description 2
- 102000006834 complement receptors Human genes 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 239000005546 dideoxynucleotide Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 239000000710 homodimer Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000017095 negative regulation of cell growth Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000006049 ring expansion reaction Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 101710122378 10 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 101710154868 60 kDa heat shock protein, mitochondrial Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108091005508 Acid proteases Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 241000607620 Aliivibrio fischeri Species 0.000 description 1
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 101000716807 Arabidopsis thaliana Protein SCO1 homolog 1, mitochondrial Proteins 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 1
- 101710085504 C-X-C motif chemokine 6 Proteins 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000003908 Cathepsin D Human genes 0.000 description 1
- 108090000258 Cathepsin D Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108010059013 Chaperonin 10 Proteins 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 101710123904 Cobalamin binding intrinsic factor Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 102100030851 Cortistatin Human genes 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- XWCFYHBHOFBVIV-UHFFFAOYSA-N Deacetylcephalosporin C Natural products S1CC(CO)=C(C(O)=O)N2C(=O)C(NC(=O)CCCC(N)C(O)=O)C21 XWCFYHBHOFBVIV-UHFFFAOYSA-N 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 101100396916 Drosophila funebris PapD gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101000925646 Enterobacteria phage T4 Endolysin Proteins 0.000 description 1
- 101710104662 Enterotoxin type C-3 Proteins 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102100030844 Exocyst complex component 1 Human genes 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 102100022366 Fatty acyl-CoA reductase 1 Human genes 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000027294 Fusi Species 0.000 description 1
- 101150077230 GAL4 gene Proteins 0.000 description 1
- 101150096040 GNAO1 gene Proteins 0.000 description 1
- 101150002389 GNAZ gene Proteins 0.000 description 1
- 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710115997 Gamma-tubulin complex component 2 Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101150007061 Gnai2 gene Proteins 0.000 description 1
- 101150041031 Gnaq gene Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100023737 GrpE protein homolog 1, mitochondrial Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 108010027814 HSP72 Heat-Shock Proteins Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101000993364 Homo sapiens Ciliary neurotrophic factor Proteins 0.000 description 1
- 101000999325 Homo sapiens Cobalamin binding intrinsic factor Proteins 0.000 description 1
- 101000824458 Homo sapiens Fatty acyl-CoA reductase 1 Proteins 0.000 description 1
- 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000829489 Homo sapiens GrpE protein homolog 1, mitochondrial Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 101001076715 Homo sapiens RNA-binding protein 39 Proteins 0.000 description 1
- 101000716809 Homo sapiens Secretogranin-1 Proteins 0.000 description 1
- 101000652229 Homo sapiens Suppressor of cytokine signaling 7 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102000026659 IL10 Human genes 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000010786 Interleukin-5 Receptors Human genes 0.000 description 1
- 108010038484 Interleukin-5 Receptors Proteins 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 102100031775 Leptin receptor Human genes 0.000 description 1
- 244000278243 Limnocharis flava Species 0.000 description 1
- 235000003403 Limnocharis flava Nutrition 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 108010093369 Multienzyme Complexes Proteins 0.000 description 1
- 102000002568 Multienzyme Complexes Human genes 0.000 description 1
- 101100283447 Mus musculus Gna11 gene Proteins 0.000 description 1
- 101100283452 Mus musculus Gna12 gene Proteins 0.000 description 1
- 101100229624 Mus musculus Gna13 gene Proteins 0.000 description 1
- 101100229628 Mus musculus Gna14 gene Proteins 0.000 description 1
- 101100229631 Mus musculus Gna15 gene Proteins 0.000 description 1
- 101100393190 Mus musculus Gnat1 gene Proteins 0.000 description 1
- 241000202956 Mycoplasma arthritidis Species 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 102100021584 Neurturin Human genes 0.000 description 1
- 108010015406 Neurturin Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010002724 Pheromone Receptors Proteins 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 102100036154 Platelet basic protein Human genes 0.000 description 1
- 102100030304 Platelet factor 4 Human genes 0.000 description 1
- 241000221945 Podospora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 101710130181 Protochlorophyllide reductase A, chloroplastic Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 108091028733 RNTP Proteins 0.000 description 1
- 101100069041 Rattus norvegicus Gnai3 gene Proteins 0.000 description 1
- 101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 102100023361 SAP domain-containing ribonucleoprotein Human genes 0.000 description 1
- 101710194492 SET-binding protein Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102100020867 Secretogranin-1 Human genes 0.000 description 1
- 108010016634 Seed Storage Proteins Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108010051611 Signal Recognition Particle Proteins 0.000 description 1
- 102000013598 Signal recognition particle Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010052160 Site-specific recombinase Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 101000882406 Staphylococcus aureus Enterotoxin type C-1 Proteins 0.000 description 1
- 101000882403 Staphylococcus aureus Enterotoxin type C-2 Proteins 0.000 description 1
- 101001057112 Staphylococcus aureus Enterotoxin type D Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 241000187433 Streptomyces clavuligerus Species 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102100030529 Suppressor of cytokine signaling 7 Human genes 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 101710117064 Trimethylamine corrinoid protein 1 Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 108700029233 VDJ Exons Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 102100038344 Vomeronasal type-1 receptor 2 Human genes 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000001876 chaperonelike Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000002962 chemical mutagen Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009133 cooperative interaction Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 108010093176 deacetoxycephalosporin C synthetase Proteins 0.000 description 1
- XWCFYHBHOFBVIV-JWKOBGCHSA-N deacetylcephalosporin C Chemical compound S1CC(CO)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CCC[C@@H](N)C(O)=O)[C@H]21 XWCFYHBHOFBVIV-JWKOBGCHSA-N 0.000 description 1
- 230000020176 deacylation Effects 0.000 description 1
- 238000005947 deacylation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000000058 esterolytic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 101150100121 gna1 gene Proteins 0.000 description 1
- 101150061883 gnai1 gene Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000009643 growth defect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 108010021083 hen egg lysozyme Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 102000004114 interleukin 20 Human genes 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000014725 late viral mRNA transcription Effects 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 108010019677 lymphotactin Proteins 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- MIFYHUACUWQUKT-GPUHXXMPSA-N penicillin N Chemical class OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CCC[C@@H](N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-GPUHXXMPSA-N 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 108010083127 phage repressor proteins Proteins 0.000 description 1
- 239000002427 pheromone receptor Substances 0.000 description 1
- 230000010422 pheromone response pathway Effects 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 125000000830 polyketide group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000016833 positive regulation of signal transduction Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 101150108007 prs gene Proteins 0.000 description 1
- 101150086435 prs1 gene Proteins 0.000 description 1
- 101150070305 prsA gene Proteins 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 101150059374 secY gene Proteins 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14041—Use of virus, viral particle or viral elements as a vector
- C12N2795/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14141—Use of virus, viral particle or viral elements as a vector
- C12N2795/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002589337A CA2589337A1 (en) | 1996-12-18 | 1997-12-17 | Methods and compositions for polypeptide engineering |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/769,062 US6335160B1 (en) | 1995-02-17 | 1996-12-18 | Methods and compositions for polypeptide engineering |
| US08/769,062 | 1996-12-18 | ||
| PCT/US1997/024239 WO1998027230A1 (en) | 1996-12-18 | 1997-12-17 | Methods and compositions for polypeptide engineering |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002589337A Division CA2589337A1 (en) | 1996-12-18 | 1997-12-17 | Methods and compositions for polypeptide engineering |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2274319A1 CA2274319A1 (en) | 1998-06-25 |
| CA2274319C true CA2274319C (en) | 2013-04-09 |
Family
ID=25084330
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2274319A Expired - Fee Related CA2274319C (en) | 1996-12-18 | 1997-12-17 | Methods and compositions for polypeptide engineering |
| CA002589337A Abandoned CA2589337A1 (en) | 1996-12-18 | 1997-12-17 | Methods and compositions for polypeptide engineering |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002589337A Abandoned CA2589337A1 (en) | 1996-12-18 | 1997-12-17 | Methods and compositions for polypeptide engineering |
Country Status (12)
| Country | Link |
|---|---|
| US (20) | US6335160B1 (enExample) |
| EP (5) | EP2202308B1 (enExample) |
| JP (2) | JP5008784B2 (enExample) |
| KR (1) | KR20000069591A (enExample) |
| AT (1) | ATE481480T1 (enExample) |
| AU (1) | AU732146B2 (enExample) |
| CA (2) | CA2274319C (enExample) |
| DE (1) | DE69739996D1 (enExample) |
| DK (2) | DK2202308T3 (enExample) |
| ES (1) | ES2351673T3 (enExample) |
| IL (1) | IL130190A0 (enExample) |
| WO (1) | WO1998027230A1 (enExample) |
Families Citing this family (461)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045289B2 (en) | 1991-09-09 | 2006-05-16 | Third Wave Technologies, Inc. | Detection of RNA Sequences |
| US7150982B2 (en) | 1991-09-09 | 2006-12-19 | Third Wave Technologies, Inc. | RNA detection assays |
| US6759226B1 (en) | 2000-05-24 | 2004-07-06 | Third Wave Technologies, Inc. | Enzymes for the detection of specific nucleic acid sequences |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5605793A (en) * | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6358709B1 (en) | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6939689B2 (en) | 1995-12-07 | 2005-09-06 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US6537776B1 (en) * | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| US6740506B2 (en) | 1995-12-07 | 2004-05-25 | Diversa Corporation | End selection in directed evolution |
| US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
| US6242211B1 (en) | 1996-04-24 | 2001-06-05 | Terragen Discovery, Inc. | Methods for generating and screening novel metabolic pathways |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| CA2276064C (en) | 1997-01-17 | 2013-12-17 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| GB9701425D0 (en) * | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US6159687A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods for generating recombined polynucleotides |
| US6153410A (en) * | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| WO1999021979A1 (en) | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Human papillomavirus vectors |
| EP1690868A1 (en) * | 1997-10-31 | 2006-08-16 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
| WO1999029902A1 (en) | 1997-12-08 | 1999-06-17 | California Institute Of Technology | Method for creating polynucleotide and polypeptide sequences |
| US6303848B1 (en) | 1998-01-16 | 2001-10-16 | Large Scale Biology Corporation | Method for conferring herbicide, pest, or disease resistance in plant hosts |
| US6426185B1 (en) | 1998-01-16 | 2002-07-30 | Large Scale Biology Corporation | Method of compiling a functional gene profile in a plant by transfecting a nucleic acid sequence of a donor plant into a different host plant in an anti-sense orientation |
| US6468745B1 (en) | 1998-01-16 | 2002-10-22 | Large Scale Biology Corporation | Method for expressing a library of nucleic acid sequence variants and selecting desired traits |
| US6759243B2 (en) * | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
| CA2318175A1 (en) | 1998-02-04 | 1999-08-12 | Invitrogen Corporation | Microarrays and uses therefor |
| US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| DE1073770T1 (de) * | 1998-04-30 | 2002-07-04 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Neuartiges Verfahren zur Identifizierung von Klonen mit einer gewünschten Biologischen Eigenschaft, ausgehend von einer Expressionsgenbank (2001/06) |
| CN1314911A (zh) | 1998-05-01 | 2001-09-26 | 麦克西根股份有限公司 | 用dna改组优化害虫抗性基因 |
| US6902918B1 (en) | 1998-05-21 | 2005-06-07 | California Institute Of Technology | Oxygenase enzymes and screening method |
| US7153655B2 (en) * | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
| KR20010052894A (ko) | 1998-06-17 | 2001-06-25 | 맥시겐, 인크. | 목적하는 특성을 보유한 폴리뉴클레오티드를 생성하는 방법 |
| US6846655B1 (en) | 1998-06-29 | 2005-01-25 | Phylos, Inc. | Methods for generating highly diverse libraries |
| US6951719B1 (en) | 1999-08-11 | 2005-10-04 | Proteus S.A. | Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained |
| FR2782323B1 (fr) * | 1998-08-12 | 2002-01-11 | Proteus | Procede de production in vitro de sequences polynucleotidiques recombinees, banques de sequences et sequences ainsi obtenues |
| US20040191772A1 (en) * | 1998-08-12 | 2004-09-30 | Dupret Daniel Marc | Method of shuffling polynucleotides using templates |
| US6991922B2 (en) * | 1998-08-12 | 2006-01-31 | Proteus S.A. | Process for in vitro creation of recombinant polynucleotide sequences by oriented ligation |
| US20030092023A1 (en) * | 1998-08-12 | 2003-05-15 | Daniel Dupret | Method of shuffling polynucleotides using templates |
| JP2002522089A (ja) * | 1998-08-12 | 2002-07-23 | マキシジェン, インコーポレイテッド | 除草剤選択性作物を生成するためのdnaシャッフリング |
| US20030104417A1 (en) * | 1998-08-12 | 2003-06-05 | Proteus S.A. | Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides |
| AU5347999A (en) | 1998-08-12 | 2000-03-06 | Maxygen, Inc. | Dna shuffling of monooxygenase genes for production of industrial chemicals |
| EP1119616A2 (en) | 1998-10-07 | 2001-08-01 | Maxygen, Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
| WO2000028018A1 (en) | 1998-11-10 | 2000-05-18 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimization of plant phenotypes |
| US6358712B1 (en) | 1999-01-05 | 2002-03-19 | Trustee Of Boston University | Ordered gene assembly |
| AU774306B2 (en) | 1999-01-05 | 2004-06-24 | Trustees Of Boston University | Improved nucleic acid cloning |
| US20040005673A1 (en) * | 2001-06-29 | 2004-01-08 | Kevin Jarrell | System for manipulating nucleic acids |
| US20030054390A1 (en) * | 1999-01-19 | 2003-03-20 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6917882B2 (en) | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| EP1151409A1 (en) * | 1999-01-18 | 2001-11-07 | Maxygen, Inc. | Methods of populating data stuctures for use in evolutionary simulations |
| US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
| EP1130093A1 (en) | 1999-01-19 | 2001-09-05 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| MXPA00009723A (es) * | 1999-02-04 | 2003-09-22 | Diversa Corp | Generacion no estocastica de vacunas y enzimas geneticas. |
| US20090130718A1 (en) * | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
| CA2361384A1 (en) | 1999-02-11 | 2000-08-17 | Sun Ai Raillard | High throughput mass spectrometry |
| US6531316B1 (en) | 1999-03-05 | 2003-03-11 | Maxyag, Inc. | Encryption of traits using split gene sequences and engineered genetic elements |
| JP2002537836A (ja) * | 1999-03-09 | 2002-11-12 | ディベルサ コーポレーション | 定方向進化におけるエンドセレクション |
| ES2324513T3 (es) * | 1999-03-18 | 2009-08-10 | Complete Genomics As | Procedimientos de clonacion y produccion de cadenas de fragmentos con contenido de informacion legible. |
| AU2005225057A1 (en) * | 1999-03-26 | 2005-12-01 | Bp Corporation North America Inc. | Synthetic ligation reassembly in directed evolution |
| AU4211600A (en) * | 1999-04-10 | 2000-11-14 | Maxygen, Inc. | Modified lipid production |
| WO2001004287A1 (en) * | 1999-07-07 | 2001-01-18 | Maxygen Aps | A method for preparing modified polypeptides |
| DK1196566T3 (da) * | 1999-07-12 | 2006-06-06 | Genentech Inc | Ekspressionsvektorer og -metoder |
| CA2377669A1 (en) * | 1999-08-12 | 2001-02-22 | Lisa M. Newman | Dna shuffling of dioxygenase genes for production of industrial chemicals |
| OA11998A (en) | 1999-08-12 | 2006-04-18 | Pfizer Prod Inc | Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins. |
| US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
| US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| WO2001029211A2 (en) * | 1999-10-19 | 2001-04-26 | Enchira Biotechnology Corporation | Method for directed evolution by random chimeragenesis on transient templates |
| WO2001029212A1 (en) * | 1999-10-19 | 2001-04-26 | Enchira Biotechnology Corporation | Methods for chimeragenesis of whole genomes or large polynucleotides |
| WO2001032712A2 (en) * | 1999-11-03 | 2001-05-10 | Maxygen, Inc. | Antibody diversity generation |
| US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
| US7115712B1 (en) | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
| EP1245955A4 (en) * | 1999-12-27 | 2004-06-16 | Toray Industries | CYTOKINE TYPE PEPTIDE |
| IL150291A0 (en) | 2000-01-11 | 2002-12-01 | Maxygen Inc | Integrated systems and methods for diversity generation and screening |
| AU2001241939A1 (en) * | 2000-02-28 | 2001-09-12 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
| EP1283909A4 (en) | 2000-05-04 | 2006-06-07 | Univ Yale | HIGH DENSITY PROTEIN ARRAYS FOR SCREENING PROTEIN ACTIVITY |
| US6479262B1 (en) * | 2000-05-16 | 2002-11-12 | Hercules, Incorporated | Solid phase enzymatic assembly of polynucleotides |
| EP1360290A2 (en) | 2000-06-23 | 2003-11-12 | Maxygen, Inc. | Co-stimulatory molecules |
| US7074590B2 (en) | 2000-06-23 | 2006-07-11 | Maxygen, Inc. | Chimeric promoters |
| US7846733B2 (en) * | 2000-06-26 | 2010-12-07 | Nugen Technologies, Inc. | Methods and compositions for transcription-based nucleic acid amplification |
| US6994963B1 (en) * | 2000-07-10 | 2006-02-07 | Ambion, Inc. | Methods for recombinatorial nucleic acid synthesis |
| US6858422B2 (en) | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
| AU2001273559A1 (en) * | 2000-07-18 | 2002-01-30 | Enchira Biotechnology Corporation | Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids |
| AU2001277014A1 (en) * | 2000-07-21 | 2002-02-05 | Trustees Of Boston University | Modular vector systems |
| US7435562B2 (en) * | 2000-07-21 | 2008-10-14 | Modular Genetics, Inc. | Modular vector systems |
| US7087415B2 (en) | 2000-07-31 | 2006-08-08 | Athena Biotechnologies, Inc. | Methods and compositions for directed gene assembly |
| AUPQ974900A0 (en) * | 2000-08-29 | 2000-09-21 | Macquarie Research Limited | Degenerate oligonucleotide gene-shuffling |
| US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| JP4280803B2 (ja) | 2000-12-08 | 2009-06-17 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 慢性リンパ性白血病細胞株および抗体を産生するためのその使用 |
| US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US6958213B2 (en) | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
| CA2430329A1 (en) * | 2000-12-13 | 2002-06-20 | Nugen Technologies, Inc. | Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof |
| US20020086292A1 (en) * | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
| US20030036641A1 (en) * | 2001-01-31 | 2003-02-20 | Padgett Hal S. | Methods for homology-driven reassembly of nucleic acid sequences |
| US20110111413A1 (en) * | 2001-02-02 | 2011-05-12 | Padgett Hal S | Method of optimizing codon usage through dna shuffling |
| CA2440560A1 (en) * | 2001-03-07 | 2002-09-19 | Xenogen Corporation | Methods of screening for introduction of dna into a target cell |
| CN1289690C (zh) * | 2001-03-09 | 2006-12-13 | 纽亘技术公司 | Rna序列扩增的方法和组合物 |
| AU2002257076A1 (en) | 2001-03-19 | 2002-10-03 | President And Fellows Of Harvard College | Nucleic acid shuffling |
| US7807408B2 (en) * | 2001-03-19 | 2010-10-05 | President & Fellows Of Harvard College | Directed evolution of proteins |
| AU2002307340A1 (en) | 2001-04-16 | 2002-10-28 | California Institute Of Technology | Peroxide-driven cytochrome p450 oxygenase variants |
| AU2002254773B2 (en) * | 2001-05-03 | 2005-12-08 | Rensselaer Polytechnic Institute | Novel methods of directed evolution |
| US20040152094A1 (en) * | 2001-05-10 | 2004-08-05 | Steffen Danielsen | Method for producing recombined polynucleotides |
| WO2002092780A2 (en) * | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| AU2002314997A1 (en) * | 2001-06-05 | 2002-12-16 | Gorilla Genomics, Inc. | Methods for low background cloning of dna using long oligonucleotides |
| WO2003008563A2 (en) | 2001-07-20 | 2003-01-30 | California Institute Of Technology | Improved cytochrome p450 oxygenases |
| DE60210298T2 (de) * | 2001-07-23 | 2006-11-02 | Dsm Ip Assets B.V. | Verfahren zur herstellung von polynucleotidvarianten |
| EP1427821B1 (en) * | 2001-08-20 | 2007-06-20 | Regenesis Bioremediation Products | Biosensor for small molecule analytes |
| US20040005709A1 (en) * | 2001-10-24 | 2004-01-08 | Hoogenboom Henricus Renerus Jacobus Mattheus | Hybridization control of sequence variation |
| DE10162727A1 (de) | 2001-12-20 | 2003-07-10 | Henkel Kgaa | Neue Alkalische Protease aus Bacillus gibsonii (DSM 14391) und Wasch-und Reinigungsmittel enthaltend diese neue Alkalische Protease |
| DE10162728A1 (de) | 2001-12-20 | 2003-07-10 | Henkel Kgaa | Neue Alkalische Protease aus Bacillus gibsonii (DSM 14393) und Wasch-und Reinigungsmittel enthaltend diese neue Alkalische Protease |
| DE10163884A1 (de) | 2001-12-22 | 2003-07-10 | Henkel Kgaa | Neue Alkalische Protease aus Bacillus sp. (DSM 14392) und Wasch- und Reinigungsmittel enthaltend diese neue Alkalische Protease |
| US20040009498A1 (en) * | 2002-01-14 | 2004-01-15 | Diversa Corporation | Chimeric antigen binding molecules and methods for making and using them |
| US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
| US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
| US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
| AU2003217716A1 (en) * | 2002-02-25 | 2003-09-09 | Cabot Corporation | Custom ligand design for biomolecular filtration and purification for bioseperation |
| WO2003075129A2 (en) | 2002-03-01 | 2003-09-12 | Maxygen, Inc. | Methods, systems, and software for identifying functional bio-molecules |
| US20050084907A1 (en) | 2002-03-01 | 2005-04-21 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| US7747391B2 (en) * | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| US7620500B2 (en) | 2002-03-09 | 2009-11-17 | Maxygen, Inc. | Optimization of crossover points for directed evolution |
| DE60323067D1 (de) * | 2002-03-11 | 2008-10-02 | Nugen Technologies Inc | Verfahren zur erzeugung doppelsträngiger dna mit einem 3'-einzelstranganteil und verwendungen dieser komplexe zur rekombination |
| US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
| WO2003089620A2 (en) | 2002-04-19 | 2003-10-30 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
| DK1504098T4 (da) * | 2002-05-17 | 2011-05-23 | Alligator Bioscience Ab | Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| WO2005003289A2 (en) | 2002-08-06 | 2005-01-13 | Verdia, Inc. | Ap1 amine oxidase variants |
| EP1539960B1 (en) * | 2002-09-09 | 2010-04-28 | Hanall Pharmaceutical Co., Ltd. | Protease-resistant modified interferon alpha polypeptides |
| US7563600B2 (en) | 2002-09-12 | 2009-07-21 | Combimatrix Corporation | Microarray synthesis and assembly of gene-length polynucleotides |
| US20060024289A1 (en) * | 2002-10-02 | 2006-02-02 | Ruggles Sandra W | Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases |
| AU2003282724B2 (en) * | 2002-10-02 | 2010-03-04 | Catalyst Biosciences, Inc. | Methods of generating and screening for proteases with altered specificity |
| US7429382B2 (en) | 2002-10-16 | 2008-09-30 | Corixa Corporation | Antibodies that bind cell-associated CA 125/O772P and methods of use thereof |
| JP2006507818A (ja) * | 2002-11-01 | 2006-03-09 | プロメガ コーポレイション | 細胞溶解のための組成物、使用方法、装置およびキット |
| US7314613B2 (en) * | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| WO2004046365A2 (en) * | 2002-11-18 | 2004-06-03 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| US20040121305A1 (en) * | 2002-12-18 | 2004-06-24 | Wiegand Roger Charles | Generation of efficacy, toxicity and disease signatures and methods of use thereof |
| EP3508578A1 (en) | 2003-03-06 | 2019-07-10 | BASF Enzymes, LLC | Amylases, nucleic acids encoding them and methods for making and using them |
| WO2005032496A2 (en) | 2003-03-07 | 2005-04-14 | Diversa Corporation | Hydrolases, nucleic acids encoding them and mehods for making and using them |
| ES2545639T3 (es) | 2003-04-04 | 2015-09-14 | Basf Enzymes Llc | Pectato liasas, ácidos nucleicos que las codifican y métodos para su preparación y uso |
| JP2006523465A (ja) * | 2003-04-14 | 2006-10-19 | ニューゲン テクノロジーズ, インコーポレイテッド | ランダムにプライミングされる複合プライマーを用いる大規模増幅 |
| MXPA05011585A (es) | 2003-04-29 | 2006-05-25 | Pioneer Hi Bred Int | Genes de glifosato-n-acetil transferasa (gat) novedosos. |
| US20040248323A1 (en) | 2003-06-09 | 2004-12-09 | Protometrix, Inc. | Methods for conducting assays for enzyme activity on protein microarrays |
| US7524664B2 (en) | 2003-06-17 | 2009-04-28 | California Institute Of Technology | Regio- and enantioselective alkane hydroxylation with modified cytochrome P450 |
| WO2005017106A2 (en) | 2003-06-17 | 2005-02-24 | California Institute Of Technology | Libraries of optimized cytochrome p450 enzymes and the optimized p450 enzymes |
| DK1641910T3 (da) | 2003-07-02 | 2013-05-21 | Verenium Corp | Glucanaser, nucleinsyrer, som koder for disse, og fremgangsmåder til at fremstille og benytte disse |
| EP1660646B1 (en) | 2003-08-11 | 2014-12-31 | California Institute Of Technology | Thermostable peroxide-driven cytochrome p450 oxygenase variants and methods of use |
| US7741089B2 (en) | 2003-08-11 | 2010-06-22 | Verenium Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
| DE602004023956D1 (de) | 2003-08-18 | 2009-12-17 | Univ California | Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon |
| PL1673457T3 (pl) | 2003-08-25 | 2011-12-30 | Amyra Biotech Ag | Nowe białka grzybów oraz kodujące je kwasy nukleinowe |
| WO2005021719A2 (en) * | 2003-08-27 | 2005-03-10 | Proterec Ltd | Libraries of recombinant chimeric proteins |
| KR20070012779A (ko) * | 2003-10-29 | 2007-01-29 | 리보메드 바이오테그놀로지스 인코포레이티드 | 반복적 올리고뉴클레오티드 합성을 위한 조성물, 방법 및검출 기법 |
| KR20120035233A (ko) | 2004-02-25 | 2012-04-13 | 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 | 신규한 바실루스 투링기엔시스 결정 폴리펩티드, 폴리뉴클레오티드, 및 이의 조성물 |
| DK1735439T3 (da) | 2004-04-12 | 2012-02-06 | Catalyst Biosciences Inc | Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1 |
| WO2005113592A2 (en) * | 2004-05-19 | 2005-12-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| BRPI0511868A (pt) | 2004-06-09 | 2008-01-15 | Pioneer Hi Bred Internacional | peptìdeo isolado, polipeptìdeo de fusão, moléculas de ácido nucléico isoladas, vetores, métodos de direcionamento de polipeptìdeos e método de identificação de peptìdeos |
| CN103173282A (zh) | 2004-06-16 | 2013-06-26 | 帝斯曼知识产权资产管理有限公司 | 对叶绿素进行酶促脱色的组合物和方法 |
| AU2005260664A1 (en) * | 2004-06-30 | 2006-01-12 | Egen Corporation | Pegylated interferon alpha-1b |
| GB0422052D0 (en) | 2004-10-04 | 2004-11-03 | Dansico As | Enzymes |
| US20070122817A1 (en) * | 2005-02-28 | 2007-05-31 | George Church | Methods for assembly of high fidelity synthetic polynucleotides |
| GB0423139D0 (en) | 2004-10-18 | 2004-11-17 | Danisco | Enzymes |
| EP1812598A1 (en) * | 2004-10-18 | 2007-08-01 | Codon Devices, Inc. | Methods for assembly of high fidelity synthetic polynucleotides |
| PT1737889E (pt) | 2004-10-19 | 2010-12-13 | Lonza Ag | Método para síntese de péptidos em fase sólida |
| JP2008519602A (ja) | 2004-11-11 | 2008-06-12 | モジュラー ジェネティクス, インコーポレイテッド | 多様性を生じるためのラダーアセンブリおよびシステム |
| WO2008076922A1 (en) * | 2006-12-15 | 2008-06-26 | Ceres, Inc. | Modulation of plant protein levels |
| WO2007087601A2 (en) * | 2006-01-25 | 2007-08-02 | Ceres, Inc. | Modulating plant protein levels |
| WO2006062971A2 (en) * | 2004-12-08 | 2006-06-15 | Ceres Inc. | Modulating plant carbon levels |
| US7335510B2 (en) * | 2004-12-16 | 2008-02-26 | Ceres, Inc. | Modulating plant nitrogen levels |
| CA2594832A1 (en) * | 2005-01-13 | 2006-07-20 | Codon Devices, Inc. | Compositions and methods for protein design |
| CA2614769A1 (en) | 2005-03-10 | 2006-09-21 | Verenium Corporation | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| AU2006227965B2 (en) | 2005-03-15 | 2013-01-31 | Bp Corporation North America Inc. | Cellulases, nucleic acids encoding them and methods for making and using them |
| US8715988B2 (en) | 2005-03-28 | 2014-05-06 | California Institute Of Technology | Alkane oxidation by modified hydroxylases |
| US11214817B2 (en) | 2005-03-28 | 2022-01-04 | California Institute Of Technology | Alkane oxidation by modified hydroxylases |
| CN101501068A (zh) * | 2005-05-18 | 2009-08-05 | 马克西根公司 | 改进的α-干扰素多肽 |
| US20060281113A1 (en) * | 2005-05-18 | 2006-12-14 | George Church | Accessible polynucleotide libraries and methods of use thereof |
| ES2335232T3 (es) | 2005-06-21 | 2010-03-23 | Xoma Technology Ltd. | Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta. |
| CA2615057A1 (en) * | 2005-07-12 | 2007-01-18 | Codon Devices, Inc. | Compositions and methods for biocatalytic engineering |
| WO2007008951A1 (en) * | 2005-07-12 | 2007-01-18 | Codon Devices, Inc. | Compositions and methods for design of non-immunogenic proteins |
| EP2535346B1 (en) | 2005-08-31 | 2017-08-02 | The Regents of The University of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| EP1929046B1 (en) * | 2005-09-07 | 2012-07-11 | Nugen Technologies, Inc. | Improved nucleic acid amplification procedure |
| GB2432366B (en) * | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| KR100759817B1 (ko) * | 2005-12-08 | 2007-09-20 | 한국전자통신연구원 | 다중 전사 인자 조절 관계 예측 방법 및 장치 |
| BRPI0707126A2 (pt) | 2006-01-12 | 2011-04-19 | Alexion Pharma Inc | anticorpos para ox-2/cd200 e uso destes |
| US8222482B2 (en) * | 2006-01-26 | 2012-07-17 | Ceres, Inc. | Modulating plant oil levels |
| WO2007092314A2 (en) | 2006-02-02 | 2007-08-16 | Verenium Corporation | Esterases and related nucleic acids and methods |
| JP2009525319A (ja) | 2006-02-02 | 2009-07-09 | ライナット ニューロサイエンス コーポレイション | trkBアンタゴニストを投与することにより肥満を治療する方法 |
| NZ595499A (en) | 2006-02-10 | 2013-05-31 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
| DK1989302T3 (en) | 2006-02-14 | 2018-07-23 | Bp Corp North America Inc | XYLANASES, NUCLEIC ACID CODING THEM AND PROCEDURES FOR THEIR PREPARATION AND USE |
| CN101437954B (zh) | 2006-03-07 | 2015-09-09 | 嘉吉公司 | 醛缩酶和编码醛缩酶的核酸以及它们的制备和使用方法 |
| EP3153580A3 (en) | 2006-03-07 | 2017-04-19 | BASF Enzymes LLC | Aldolases, nucleic acids encoding them and methods for making and using them |
| US20070231805A1 (en) * | 2006-03-31 | 2007-10-04 | Baynes Brian M | Nucleic acid assembly optimization using clamped mismatch binding proteins |
| WO2007133804A2 (en) * | 2006-05-15 | 2007-11-22 | Ceres, Inc. | Modulation of oil levels in plants |
| WO2007136834A2 (en) * | 2006-05-19 | 2007-11-29 | Codon Devices, Inc. | Combined extension and ligation for nucleic acid assembly |
| AR061365A1 (es) * | 2006-06-13 | 2008-08-20 | Athenix Corp | Metodos para generar diversidad genetica mediante mutagenesis con permutaciones |
| WO2007149570A2 (en) * | 2006-06-21 | 2007-12-27 | Ceres, Inc. | Modulation of protein levels in plants |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| US8252559B2 (en) | 2006-08-04 | 2012-08-28 | The California Institute Of Technology | Methods and systems for selective fluorination of organic molecules |
| US8026085B2 (en) | 2006-08-04 | 2011-09-27 | California Institute Of Technology | Methods and systems for selective fluorination of organic molecules |
| MX369001B (es) | 2006-08-04 | 2019-10-24 | Basf Enzymes Llc | Glucanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas. |
| US7727745B2 (en) * | 2006-08-14 | 2010-06-01 | Bio-Id Diagnostic Inc. | Synthesis of single-stranded DNA |
| CA2660705A1 (en) * | 2006-08-15 | 2008-02-21 | Commonwealth Scientific And Industrial Research Organisation | Reassortment by fragment ligation |
| US8158411B2 (en) | 2006-08-21 | 2012-04-17 | Samsung Electronics Co., Ltd. | Method of separating microorganism using nonplanar solid substrate and device for separating microorganism using the same |
| WO2008027558A2 (en) | 2006-08-31 | 2008-03-06 | Codon Devices, Inc. | Iterative nucleic acid assembly using activation of vector-encoded traits |
| EP2057274B1 (en) | 2006-09-21 | 2013-12-11 | DSM IP Assets B.V. | Phospholipases, nucleic acids encoding them and methods for making and using them |
| WO2008036916A2 (en) | 2006-09-21 | 2008-03-27 | Verenium Corporation | Phytases, nucleic acids encoding them and methods for making and using them |
| AU2007336732B2 (en) | 2006-12-21 | 2013-05-02 | Syngenta Participations Ag | Amylases and glucoamylases, nucleic acids encoding them and methods for making and using them |
| DE102007003143A1 (de) | 2007-01-16 | 2008-07-17 | Henkel Kgaa | Neue Alkalische Protease aus Bacillus gibsonii und Wasch- und Reinigungsmittel enthaltend diese neue Alkalische Protease |
| US20080175668A1 (en) * | 2007-01-18 | 2008-07-24 | Larry Wayne Haese | Graywater recycling system including rainwater recovery |
| AU2008210495B2 (en) | 2007-01-30 | 2014-02-27 | Bp Corporation North America, Inc. | Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them |
| US8143046B2 (en) | 2007-02-07 | 2012-03-27 | Danisco Us Inc., Genencor Division | Variant Buttiauxella sp. phytases having altered properties |
| US7820421B2 (en) | 2007-02-08 | 2010-10-26 | Codexis, Inc. | Ketoreductases and uses thereof |
| SG178753A1 (en) | 2007-02-12 | 2012-03-29 | Codexis Inc | Structure-activity relationships |
| CA2678451A1 (en) | 2007-02-20 | 2008-08-28 | Robert A. Horlick | Somatic hypermutation systems |
| US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
| US8986684B2 (en) | 2007-07-25 | 2015-03-24 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| MX353478B (es) | 2007-07-31 | 2018-01-15 | Bp Corp North America Inc Star | Ensamblaje combinacional de sitios multiples, a la medida. |
| US20110166027A1 (en) * | 2007-08-21 | 2011-07-07 | Affomix Corporation | Interaction screening methods, systems and devices |
| WO2009029554A2 (en) | 2007-08-24 | 2009-03-05 | Codexis, Inc. | Improved ketoreductase polypeptides for the stereoselective production of (r)-3-hydroxythiolane |
| JP5646328B2 (ja) | 2007-10-01 | 2014-12-24 | コデクシス, インコーポレイテッド | アゼチジノンの生産のためのケトレダクターゼポリペプチド |
| MX2010003600A (es) | 2007-10-03 | 2010-12-14 | Verenium Corp | Xilanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas. |
| DE102007051092A1 (de) | 2007-10-24 | 2009-04-30 | Henkel Ag & Co. Kgaa | Subtilisin aus Becillus pumilus und Wasch- und Reinigungsmittel enthaltend dieses neue Subtilisin |
| EP2222697B1 (en) | 2007-11-01 | 2012-12-05 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| DK2238261T3 (da) | 2008-01-03 | 2014-02-10 | Verenium Corp | Isomeraser, nukleinsyrer der koder for dem og fremgangsmåder til fremstilling og anvendelse deraf |
| CN101965397B (zh) | 2008-01-03 | 2016-09-28 | 巴斯夫酶有限责任公司 | 转移酶和氧化还原酶、编码它们的核酸以及其制备和应用方法 |
| WO2009097673A1 (en) * | 2008-02-07 | 2009-08-13 | Bio-Id Diagnostic Inc. | Synthesis of single-stranded dna |
| WO2009102899A1 (en) | 2008-02-12 | 2009-08-20 | Codexis, Inc. | Method of generating an optimized diverse population of variants |
| US8034568B2 (en) * | 2008-02-12 | 2011-10-11 | Nugen Technologies, Inc. | Isothermal nucleic acid amplification methods and compositions |
| US8768871B2 (en) | 2008-02-12 | 2014-07-01 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
| ES2535011T3 (es) * | 2008-02-15 | 2015-05-04 | Ceres Inc. | Tolerancia a la sequía y al calor en plantas |
| US7846666B2 (en) | 2008-03-21 | 2010-12-07 | Nugen Technologies, Inc. | Methods of RNA amplification in the presence of DNA |
| EP2297310A2 (en) | 2008-05-23 | 2011-03-23 | E. I. du Pont de Nemours and Company | Novel dgat genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
| US8383346B2 (en) | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
| US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| DK3023494T3 (en) | 2008-06-13 | 2019-02-25 | Codexis Inc | PROCEDURE FOR SYNTHESIS OF POLYNUCLEOTIDE VARIETIES |
| ES2438576T3 (es) | 2008-06-24 | 2014-01-17 | Codexis, Inc. | Procesos biocatalíticos para la preparación de compuestos de prolina bicíclica fusionada considerablemente pura estereoméricamente |
| US8288131B2 (en) | 2008-08-27 | 2012-10-16 | Codexis, Inc. | Ketoreductase polypeptides and uses thereof |
| US8288141B2 (en) | 2008-08-27 | 2012-10-16 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| EP2329013B1 (en) | 2008-08-27 | 2015-10-28 | Codexis, Inc. | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
| US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| SG10201404330VA (en) | 2008-08-29 | 2014-10-30 | Codexis Inc | Ketoreductase Polypeptides For The Stereoselective Production Of (4S)-3[(5S)-5(4-Fluorophenyl)-5-Hydroxypentanoyl]-4-Phenyl-1,3-Oxazolidin-2-One |
| WO2010036986A2 (en) | 2008-09-26 | 2010-04-01 | Tocagen Inc. | Recombinant vectors |
| US8247192B2 (en) | 2008-11-10 | 2012-08-21 | Codexis, Inc. | Penicillin-G acylases |
| EP2382308B1 (en) | 2008-12-25 | 2015-03-04 | Codexis, Inc. | Enone reductases |
| ES2840000T3 (es) | 2009-01-08 | 2021-07-06 | Codexis Inc | Polipéptidos de transaminasa |
| WO2010091021A2 (en) * | 2009-02-03 | 2010-08-12 | Complete Genomics, Inc. | Oligomer sequences mapping |
| WO2010091024A1 (en) * | 2009-02-03 | 2010-08-12 | Complete Genomics, Inc. | Oligomer sequences mapping |
| US8738296B2 (en) * | 2009-02-03 | 2014-05-27 | Complete Genomics, Inc. | Indexing a reference sequence for oligomer sequence mapping |
| SG173815A1 (en) | 2009-02-26 | 2011-09-29 | Codexis Inc | Transaminase biocatalysts |
| EP2401369B1 (en) | 2009-02-26 | 2014-12-24 | Codexis, Inc. | Beta-glucosidase variant enzymes and related polynucleotides |
| DK2406399T3 (en) * | 2009-03-09 | 2018-03-12 | Bioatla Llc | MIRAC PROTEINS |
| CA2754580C (en) | 2009-03-17 | 2014-06-17 | Codexis, Inc. | Variant endoglucanases and related polynucleotides |
| EP2414506B1 (en) | 2009-03-31 | 2017-05-03 | Codexis, Inc. | Improved endoglucanases |
| US20120100997A1 (en) | 2009-04-24 | 2012-04-26 | University Of Southern California | Cd133 polymorphisms and expression predict clinical outcome in patients with cancer |
| EP2430441B1 (en) * | 2009-04-29 | 2018-06-13 | Complete Genomics, Inc. | Method and system for calling variations in a sample polynucleotide sequence with respect to a reference polynucleotide sequence |
| BRPI1011160A8 (pt) | 2009-05-21 | 2018-01-02 | Verenium Corp | Fitases, preparação de proteína que as compreende, e seus usos |
| CA2762616C (en) | 2009-06-16 | 2015-08-18 | Codexis, Inc. | Beta-glucosidase variant enzymes and related polynucleotides |
| US8772010B2 (en) | 2009-06-16 | 2014-07-08 | Codexis, Inc. | β-Glucosidase variants |
| EP2446026B1 (en) | 2009-06-22 | 2017-08-09 | Codexis, Inc. | Transaminase reactions |
| EP3409765B1 (en) | 2009-06-22 | 2021-08-04 | Codexis, Inc. | Ketoreductase-mediated stereoselective route to alpha chloroalcohols |
| US8614081B2 (en) | 2009-07-23 | 2013-12-24 | Codexis, Inc. | Nitrilase biocatalysts |
| SG178456A1 (en) | 2009-08-19 | 2012-04-27 | Codexis Inc | Ketoreductase polypeptides for the preparation of phenylephrine |
| IN2012DN01359A (enExample) | 2009-08-20 | 2015-06-05 | Pioneer Hi Bred Int | |
| EP2473604B1 (en) | 2009-09-04 | 2017-01-11 | Codexis, Inc. | Variant cbh2 cellulases and related polynucleotides |
| EP2478137B1 (en) | 2009-09-18 | 2017-09-13 | Codexis, Inc. | Reduced codon mutagenesis |
| ES2538396T3 (es) | 2009-09-30 | 2015-06-19 | Codexis, Inc. | C1 ß-glucosidasa recombinante para la producción de azúcares a partir de biomasa celulósica |
| UA109884C2 (uk) | 2009-10-16 | 2015-10-26 | Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування | |
| UA111708C2 (uk) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | Спосіб рафінування олії |
| WO2011063080A2 (en) | 2009-11-20 | 2011-05-26 | Codexis, Inc. | Mutli-cellulase enzyme compositions for hydrolysis of cellulosic biomass |
| WO2011066187A1 (en) | 2009-11-25 | 2011-06-03 | Codexis, Inc. | Recombinant thermoascus aurantiacus beta-glucosidase variants for production of fermentable sugars from cellulosic biomass |
| EP2504017B1 (en) * | 2009-11-25 | 2014-01-08 | Codexis, Inc. | Recombinant beta-glucosidase variants for production of soluble sugars from cellulosic biomass |
| EP2510089B1 (en) | 2009-12-08 | 2015-10-21 | Codexis, Inc. | Synthesis of prazole compounds |
| WO2011084757A1 (en) | 2009-12-21 | 2011-07-14 | University Of Southern California | Germline polymorphisms in the sparc gene associated with clinical outcome in gastric cancer |
| WO2011082304A1 (en) | 2009-12-31 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
| WO2011085334A1 (en) | 2010-01-11 | 2011-07-14 | University Of Southern California | Cd44 polymorphisms predict clinical outcome in patients with gastric cancer |
| US9080192B2 (en) | 2010-02-10 | 2015-07-14 | Codexis, Inc. | Processes using amino acid dehydrogenases and ketoreductase-based cofactor regenerating system |
| US8986965B2 (en) | 2010-03-31 | 2015-03-24 | Codexis, Inc. | Production of monoterpenes |
| WO2011140219A1 (en) | 2010-05-04 | 2011-11-10 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
| WO2011143274A1 (en) | 2010-05-10 | 2011-11-17 | Perseid Therapeutics | Polypeptide inhibitors of vla4 |
| EP2569426A4 (en) | 2010-05-14 | 2013-10-09 | Codexis Inc | ZELLBIOHYDROLASE VARIANTS |
| WO2011150313A1 (en) | 2010-05-28 | 2011-12-01 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| US8852900B2 (en) | 2010-06-17 | 2014-10-07 | Codexis, Inc. | Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol |
| WO2012006114A2 (en) | 2010-06-28 | 2012-01-12 | Codexis, Inc. | Fatty alcohol forming acyl reductases (fars) and methods of use thereof |
| AU2011272878B2 (en) | 2010-06-30 | 2015-04-23 | Codexis, Inc. | Highly stable beta-class carbonic anhydrases useful in carbon capture systems |
| CA2805941A1 (en) | 2010-08-13 | 2012-02-16 | Pioneer Hi-Bred International, Inc. | Methods and compositions for targeting sequences of interest to the chloroplast |
| CA2808098C (en) | 2010-08-16 | 2020-03-10 | Merck Sharp & Dohme Corp. | Process for preparing aminocyclohexyl ether compounds |
| EP2606139B1 (en) | 2010-08-16 | 2015-07-15 | Codexis, Inc. | Biocatalysts and methods for the synthesis of (1r,2r)-2-(3,4-dimethoxyphenethoxy)cyclohexanamine |
| US9322027B2 (en) | 2010-08-20 | 2016-04-26 | Shell Oil Company | Expression constructs comprising fungal promoters |
| CN103080306B (zh) | 2010-08-20 | 2015-02-18 | 科德克希思公司 | 糖苷水解酶61家族蛋白在纤维素加工中的用途 |
| BR112013010812A2 (pt) | 2010-11-02 | 2016-07-12 | Codexis Inc | composições e métodos para produção de açúcares fermentáveis. |
| DK2635671T3 (en) | 2010-11-02 | 2016-10-24 | Codexis Inc | Improved fungi strains |
| EP2637780B1 (en) | 2010-11-12 | 2022-02-09 | Gen9, Inc. | Protein arrays and methods of using and making the same |
| EP3000883B8 (en) | 2010-11-12 | 2018-02-28 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
| US9267159B2 (en) | 2010-12-08 | 2016-02-23 | Codexis, Inc. | Biocatalysts and methods for the synthesis of armodafinil |
| WO2012088159A2 (en) | 2010-12-21 | 2012-06-28 | Codexis, Inc. | Endoglucanase variants |
| WO2012135110A1 (en) | 2011-03-30 | 2012-10-04 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| US20120258866A1 (en) * | 2011-04-05 | 2012-10-11 | Full Spectrum Genetics, Inc. | Multi-dimensional selection of protein mutants using high throughput sequence analysis |
| US9605250B2 (en) | 2011-04-12 | 2017-03-28 | Gangagen, Inc. | Chimeric antibacterial polypeptides |
| HUE038800T2 (hu) | 2011-04-13 | 2018-11-28 | Codexis Inc | Biokatalitikus eljárás eszlikarbazepin és ennek analógjai elõállítására |
| HUE042817T2 (hu) | 2011-06-28 | 2019-07-29 | Codexis Inc | Fehérjevariánsok elõállítása régiókeveréssel |
| US8778652B2 (en) | 2011-06-30 | 2014-07-15 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| WO2013016207A2 (en) | 2011-07-22 | 2013-01-31 | California Institute Of Technology | Stable fungal cel6 enzyme variants |
| EP2748317B1 (en) | 2011-08-22 | 2017-04-19 | Codexis, Inc. | Gh61 glycoside hydrolase protein variants and cofactors that enhance gh61 activity |
| EP2748187A4 (en) | 2011-08-23 | 2015-03-04 | Codexis Inc | VARIANTS OF CELLOBIOHYDROLASE |
| IL280334B2 (en) | 2011-08-26 | 2023-09-01 | Gen9 Inc | Preparations and methods for high-fidelity assembly of nucleic acids |
| EP2753640B1 (en) | 2011-09-08 | 2016-03-09 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
| EP2760997A4 (en) | 2011-09-30 | 2015-02-11 | Codexis Inc | MUSHROOM PROTEASE |
| US9139819B2 (en) | 2011-11-18 | 2015-09-22 | Codexis, Inc. | Biocatalysts for the preparation of hydroxy substituted carbamates |
| BR112014015030A2 (pt) | 2011-12-20 | 2017-06-13 | Codexis Inc | variantes da endoflucanase 1b (eg1b) |
| WO2013096082A1 (en) | 2011-12-20 | 2013-06-27 | Codexis, Inc. | Fatty alcohol forming acyl reductase (far) variants and methods of use |
| US9150853B2 (en) | 2012-03-21 | 2015-10-06 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
| DK2828385T3 (en) | 2012-03-23 | 2018-03-12 | Codexis Inc | BIOCATALIZATORS AND METHODS FOR SYNTHETIZING DERIVATIVES AND TRYPTAMIN AND TRYPTAMINE ANALOGS |
| WO2013159055A1 (en) | 2012-04-20 | 2013-10-24 | Codexis, Inc. | Production of fatty alcohols from engineered microorganisms |
| EP3543350B1 (en) | 2012-04-24 | 2021-11-10 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
| WO2013166113A1 (en) | 2012-05-04 | 2013-11-07 | E. I. Du Pont De Nemours And Company | Compositions and methods comprising sequences having meganuclease activity |
| CN104428412B (zh) | 2012-05-08 | 2017-09-08 | 科德克希思公司 | 用于化合物的羟基化的生物催化剂和方法 |
| HUE036947T2 (hu) | 2012-05-11 | 2018-08-28 | Codexis Inc | Átalakított iminreduktázok és eljárások keton- és aminvegyületek reduktív aminálására |
| WO2013172954A1 (en) | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc | Peptide and peptidomimetic inhibitors |
| BR112014031024A2 (pt) | 2012-06-11 | 2017-06-27 | Codexis Inc | xilanases e xilosidases fúngicas. |
| JP6509727B2 (ja) | 2012-06-25 | 2019-05-15 | ギンゴー バイオワークス, インコーポレイテッド | 核酸アセンブリおよび高処理シークエンシングのための方法 |
| WO2014015278A1 (en) | 2012-07-20 | 2014-01-23 | Codexis, Inc. | Production of fatty alcohols from engineered microorganisms |
| US9506087B2 (en) | 2012-08-07 | 2016-11-29 | Codexis, Inc. | Glucose and xylose co-utilization in E. coli |
| EP3450549B1 (en) | 2012-10-29 | 2020-09-30 | University Of Rochester | Artemisinin derivatives, methods for their preparation and their use as antimalarial agents |
| AU2013348272A1 (en) | 2012-11-20 | 2015-05-14 | Shell Internationale Research Maatschappij B.V. | Pentose fermentation by a recombinant microorganism |
| PT2928865T (pt) | 2012-12-07 | 2018-06-11 | Merck Sharp & Dohme | Processo de transaminação biocatalítica |
| WO2014092458A1 (ko) * | 2012-12-11 | 2014-06-19 | 연세대학교 산학협력단 | 코돈 조합화 및 변이유발을 이용한 유전자 라이브러리의 합성 방법 |
| US9512447B2 (en) | 2012-12-14 | 2016-12-06 | Codexis, Inc. | Modified native beta-ketoacyl-ACP synthases and engineered microorganisms |
| DK2935572T3 (da) | 2012-12-21 | 2020-11-16 | Codexis Inc | Modificerede biokatalysatorer og fremgangsmåder til syntetisering af chirale aminer |
| CN105051180B (zh) | 2013-01-18 | 2020-06-12 | 科德克希思公司 | 用于碳青霉烯类合成的工程化的生物催化剂 |
| EP4398255A3 (en) | 2013-01-31 | 2024-09-04 | Codexis, Inc. | Methods, systems, and software for identifying bio-molecules with interacting components |
| ES2694327T3 (es) | 2013-02-28 | 2018-12-19 | Codexis, Inc. | Polipéptidos de transaminasa modificados por biocatálisis industrial |
| EP2970995A1 (en) | 2013-03-14 | 2016-01-20 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
| AU2014236162A1 (en) | 2013-03-14 | 2015-09-17 | Arzeda Corp. | Compositions having dicamba decarboxylase activity and methods of use |
| US9670493B2 (en) | 2013-03-14 | 2017-06-06 | Codexis, Inc. | Low-phosphate repressible promoter |
| BR112015023709A2 (pt) | 2013-03-15 | 2017-07-18 | Pioneer Hi Bred Int | polipeptídeo phi-4, polinucleotídeo, composição, método para inibir o crescimento, método para controlar uma população, planta, semente, cassete de expressão, método para expressar em uma planta um polinucleotídeo, método para proteger uma planta, proteína de fusão |
| HRP20190928T1 (hr) | 2013-04-18 | 2019-07-26 | Codexis, Inc. | Modificirani fenilalanin amonijak-liazni polipeptidi |
| BR112016003225B1 (pt) | 2013-08-16 | 2022-10-25 | Pioneer Hi-Bred International, Inc. | Polipeptídeo pip-47, polipeptídeo pip-47 quimérico, composição, proteína de fusão, método para controlar uma população de inseto-praga, método para inibir o crescimento ou matar um inseto-praga, construto de dna, polinucleotídeo isolado, cassete de expressão, método de obtenção de uma planta transgênica e método para controlar infestação de inseto |
| US10726942B2 (en) | 2013-08-23 | 2020-07-28 | Complete Genomics, Inc. | Long fragment de novo assembly using short reads |
| BR112016005543B1 (pt) | 2013-09-13 | 2022-03-08 | Pioneer Hi-Bred International, Inc | Polipeptídeo pip-72 recombinante, construto de dna, método de obtenção de planta transgênica, célula hospedeira, composição, proteína de fusão, método para controlar uma população de praga de inseto, método para inibir o crescimento ou matar uma praga de inseto, método para controlar uma infestação de insetos em uma planta transgênica, método para identificar em uma amostra biológica uma sequência de nucleotídeos, método para identificar em uma amostra um polipeptídeo pip-72 |
| JP6857029B2 (ja) | 2013-09-27 | 2021-04-14 | コデクシス, インコーポレイテッド | 酵素バリアントの自動スクリーニング |
| JP6643987B2 (ja) | 2013-11-13 | 2020-02-12 | コデクシス, インコーポレイテッド | ケトン化合物およびアミン化合物の還元的アミノ化のための操作されたイミンレダクターゼおよび方法 |
| WO2015100277A2 (en) | 2013-12-23 | 2015-07-02 | University Of Rochester | Methods and compositions for ribosomal synthesis of macrocyclic peptides |
| WO2015120270A1 (en) | 2014-02-07 | 2015-08-13 | Pioneer Hi Bred International, Inc. | Insecticidal proteins and methods for their use |
| US10227608B2 (en) | 2014-02-07 | 2019-03-12 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins from plants and methods for their use |
| US20170136102A1 (en) | 2014-03-27 | 2017-05-18 | Umender Kumar SHARMA | Phage-derived compositions for improved mycobacterial therapy |
| US9605252B2 (en) | 2014-04-16 | 2017-03-28 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| DK3167052T3 (da) | 2014-07-09 | 2020-02-10 | Codexis Inc | P450-bm3-varianter med forbedret aktivitet |
| WO2016014725A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
| WO2016033296A1 (en) | 2014-08-28 | 2016-03-03 | Codexis, Inc. | N-substituted 4-aminoquinazoline derivatives and methods of use |
| US10045987B2 (en) | 2014-08-28 | 2018-08-14 | Codexis, Inc. | Imidazoyl anilide derivatives and methods of use |
| EP3207143B1 (en) | 2014-10-16 | 2023-11-22 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| US10370648B2 (en) | 2014-11-25 | 2019-08-06 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| WO2016183532A1 (en) | 2015-05-13 | 2016-11-17 | Synlogic, Inc. | Bacteria engineered to treat a disease or disorder |
| EP3237621B1 (en) | 2014-12-22 | 2023-04-19 | Codexis, Inc. | Human alpha-galactosidase variants |
| EP3244727B1 (en) | 2015-01-15 | 2025-10-22 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| US10696953B2 (en) | 2015-02-10 | 2020-06-30 | Codexis, Inc. | Ketoreductase polypeptides for the synthesis of chiral compounds |
| US10876132B2 (en) | 2015-03-11 | 2020-12-29 | Pioneer Hi-Bred International, Inc. | Insecticidal combinations of PIP-72 and methods of use |
| EP3292136B1 (en) | 2015-05-07 | 2021-02-17 | Codexis, Inc. | Penicillin-g acylases |
| RU2017144238A (ru) | 2015-05-19 | 2019-06-19 | Пайонир Хай-Бред Интернэшнл, Инк. | Инсектицидные белки и способы их применения |
| US11291693B2 (en) | 2015-06-25 | 2022-04-05 | Synlogic Operating Company, Inc. | Bacteria engineered to treat metabolic diseases |
| CN108271374B (zh) | 2015-07-07 | 2021-09-21 | 科德克希思公司 | 具有改进的活性的新颖p450-bm3变体 |
| BR122023016256B8 (pt) | 2015-08-06 | 2024-04-30 | Du Pont | Polipeptídeo inseticida recombinante, polinucleotídeo recombinante, construto de dna, método de obtenção de uma planta transgênica ou célula de planta transgênica, composição, proteína de fusão, método para controlar uma praga, método para inibir crescimento ou para exterminar uma população de pragas e uso do polipeptídeo |
| US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| JP6821598B2 (ja) | 2015-12-07 | 2021-01-27 | ザイマージェン インコーポレイテッド | Corynebacterium glutamicum由来のプロモーター |
| EP3390431A1 (en) | 2015-12-18 | 2018-10-24 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| WO2017123676A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof |
| EP3402497A1 (en) | 2016-01-11 | 2018-11-21 | Synlogic Operating Company, Inc. | Bacteria engineered to treat metabolic diseases |
| WO2017123592A1 (en) | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Bacteria engineered to treat disorders associated with bile salts |
| WO2017139708A1 (en) | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat nonalcoholic steatohepatitis (nash) |
| US11008585B2 (en) | 2016-05-04 | 2021-05-18 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| MX389364B (es) | 2016-05-05 | 2025-03-19 | Codexis Inc | Penicilina g acilasas |
| EP3469088B1 (en) | 2016-06-09 | 2023-09-06 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
| JP2019517801A (ja) | 2016-06-15 | 2019-06-27 | コデクシス, インコーポレイテッド | 操作されたβ−グルコシダーゼおよびグルコシル化方法 |
| EP3478833A4 (en) | 2016-06-30 | 2019-10-02 | Zymergen, Inc. | METHOD FOR PRODUCING A BACTERIAL HEMOGLOBIN LIBRARY AND ITS USE |
| US10544411B2 (en) | 2016-06-30 | 2020-01-28 | Zymergen Inc. | Methods for generating a glucose permease library and uses thereof |
| EP3478052B1 (en) | 2016-07-01 | 2021-08-25 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins from plants and methods for their use |
| SG10202111589RA (en) | 2016-08-26 | 2021-11-29 | Codexis Inc | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| WO2018084936A1 (en) | 2016-11-01 | 2018-05-11 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| CN110088123B (zh) | 2016-12-14 | 2023-10-20 | 先锋国际良种公司 | 杀昆虫蛋白及其使用方法 |
| CA3046226A1 (en) | 2016-12-22 | 2018-06-28 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| WO2018129130A1 (en) | 2017-01-05 | 2018-07-12 | Codexis, Inc. | Penicillin-g acylases |
| WO2018144675A1 (en) | 2017-02-03 | 2018-08-09 | Codexis, Inc. | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
| US20190390219A1 (en) | 2017-02-08 | 2019-12-26 | Pioneer Hi-Bred International, Inc. | Insecticidal combinations of plant derived insecticidal proteins and methods for their use |
| AU2018217495B2 (en) | 2017-02-13 | 2021-03-04 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| JP7179014B2 (ja) | 2017-04-24 | 2022-11-28 | テサロ, インコーポレイテッド | ニラパリブの製造方法 |
| CN110831618B (zh) | 2017-04-27 | 2023-08-25 | 科德克希思公司 | 酮还原酶多肽及多核苷酸 |
| CN110914415B (zh) | 2017-05-08 | 2024-09-17 | 科德克希思公司 | 工程化连接酶变体 |
| RU2019140646A (ru) | 2017-05-11 | 2021-06-11 | Пайонир Хай-Бред Интернэшнл, Инк. | Инсектицидные белки и способы их применения |
| JP7122009B2 (ja) | 2017-06-14 | 2022-08-19 | コデクシス, インコーポレイテッド | 産業上の生体触媒作用のための操作されたトランスアミナーゼポリペプチド |
| CA3064577A1 (en) | 2017-06-27 | 2019-01-03 | Codexis, Inc. | Penicillin-g acylases |
| JP2020530267A (ja) | 2017-06-30 | 2020-10-22 | コデクシス, インコーポレイテッド | T7 rnaポリメラーゼバリアント |
| EP3645711A4 (en) | 2017-06-30 | 2021-04-21 | Codexis, Inc. | T7 RNA POLYMERASE VARIANTS |
| WO2019040335A1 (en) | 2017-08-19 | 2019-02-28 | University Of Rochester | MICHELOLID DERIVATIVES, PREPARATION METHODS AND THEIR USE AS ANTICANCER AND ANTI-INFLAMMATORY AGENTS |
| WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
| SG11202003094PA (en) | 2017-11-07 | 2020-05-28 | Codexis Inc | Transglutaminase variants |
| MX2020006222A (es) | 2017-12-13 | 2020-08-31 | Codexis Inc | Polipeptidos de carboxiesterasa para acoplamiento de amidas. |
| EP4471137A3 (en) | 2017-12-13 | 2025-02-19 | GlaxoSmithKline Intellectual Property Development Ltd | Carboxyesterase biocatalysts |
| US11857606B2 (en) | 2017-12-14 | 2024-01-02 | Bactoclear Holdings Pte. Ltd. | Therapeutic bacteriocins |
| EP4659582A2 (en) | 2018-03-14 | 2025-12-10 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins from plants and methods for their use |
| MX2020009435A (es) | 2018-03-14 | 2020-11-11 | Pioneer Hi Bred Int | Proteinas con actividad insecticida de plantas y metodos para sus usos. |
| US10900055B2 (en) | 2018-06-12 | 2021-01-26 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| MX2021000323A (es) | 2018-07-09 | 2021-03-25 | Codexis Inc | Enzimas de variante de pantotenato quinasa modificadas geneticamente. |
| MX2021000327A (es) | 2018-07-09 | 2021-03-25 | Codexis Inc | Enzimas de variante de fosforilasa de nucleosido de purina modificadas geneticamente. |
| MX2021000326A (es) | 2018-07-09 | 2021-03-25 | Codexis Inc | Desoxirribosa-fosfato aldolasas modificadas geneticamente. |
| MX2021000328A (es) | 2018-07-09 | 2021-03-25 | Codexis Inc | Enzimas de variantes de galactosa oxidasa modificadas geneticamente. |
| CN112601821A (zh) | 2018-07-09 | 2021-04-02 | 科德克希思公司 | 工程化磷酸戊糖变位酶变体酶 |
| US11198861B2 (en) | 2018-07-12 | 2021-12-14 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| JP7584401B2 (ja) | 2018-07-30 | 2024-11-15 | テイト アンド ライル ソリューションズ ユー・エス・エー エル・エル・シー | 操作されたグリコシルトランスフェラーゼおよびステビオールグリコシドのグルコシル化方法 |
| KR20210084590A (ko) | 2018-10-29 | 2021-07-07 | 코덱시스, 인코포레이티드 | 조작된 dna 중합효소 변이체 |
| AU2019397401A1 (en) | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| KR102898199B1 (ko) | 2018-12-20 | 2025-12-09 | 코덱시스, 인코포레이티드 | 인간 알파 갈락토시다제 변이체 |
| WO2020150125A1 (en) | 2019-01-15 | 2020-07-23 | Codexis, Inc. | Engineered transaminase polypeptides |
| JP7677630B2 (ja) | 2019-05-01 | 2025-05-15 | コデクシス, インコーポレイテッド | 操作されたグルコースデヒドロゲナーゼ、ならびにケトンおよびアミン化合物の還元的アミノ化を行うための方法 |
| US12215368B2 (en) | 2019-05-01 | 2025-02-04 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| EP3994153A4 (en) | 2019-07-02 | 2023-10-11 | Codexis, Inc. | MODIFIED ACETATE KINASE VARIANT ENZYMES |
| BR112021026326A2 (pt) | 2019-07-02 | 2022-02-08 | Codexis Inc | Sacarose fosforilase engenheirada, composição, sequência de polinucleotídeo, vetor de expressão, célula hospedeira, e, método para produzir uma sacarose fosforilase engenheirada |
| ES3007439T3 (en) | 2019-08-30 | 2025-03-20 | Nestle Sa | Engineered lipase variants |
| US12012620B2 (en) | 2019-09-12 | 2024-06-18 | Codexis, Inc. | Peroxidase activity towards 10-acetyl-3,7-dihydroxyphenoxazine |
| EP4042149A1 (en) | 2019-10-02 | 2022-08-17 | Abbott Diabetes Care Inc. | Detection of analytes by protein switches |
| JP7720098B2 (ja) | 2019-11-26 | 2025-08-07 | コデクシス, インコーポレイテッド | 化合物のヒドロキシル化のための生体触媒および方法 |
| CA3165484A1 (en) | 2019-12-20 | 2021-06-24 | Codexis, Inc. | Engineered acid alpha-glucosidase variants |
| EP4087932A4 (en) | 2020-01-10 | 2024-01-17 | The Regents of the University of California | Biosynthetic platform for the production of olivetolic avid and analogues of olivetolic acid |
| PH12022551776A1 (en) | 2020-02-04 | 2023-11-29 | Codexis Inc | Engineered leucine decarboxylases |
| US11788071B2 (en) | 2020-04-10 | 2023-10-17 | Codexis, Inc. | Engineered transaminase polypeptides |
| MX2022013462A (es) | 2020-04-27 | 2022-11-16 | 4D Molecular Therapeutics Inc | Variantes, formulaciones y metodos adeno-asociados para suministro pulmonar. |
| EP4182466A2 (en) | 2020-07-14 | 2023-05-24 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| CA3191867A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered protease variants |
| WO2022047264A1 (en) | 2020-08-28 | 2022-03-03 | Codexis, Inc. | Engineered amylase variants |
| US20220186231A1 (en) | 2020-12-11 | 2022-06-16 | Willow Biosciences, Inc. | Recombinant acyl activating enzyme (aae) genes for enhanced biosynthesis of cannabinoids and cannabinoid precursors |
| EP4262804A4 (en) | 2020-12-18 | 2025-02-12 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
| IL305922A (en) | 2021-04-02 | 2023-11-01 | Codexis Inc | Transgenic enzymes of variant guanylate kinase |
| CN117120600A (zh) | 2021-04-02 | 2023-11-24 | 科德克希思公司 | 工程化腺苷酸激酶变体酶 |
| WO2022212835A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
| CA3214975A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered cyclic gmp-amp synthase (cgas) variant enzymes |
| TW202313969A (zh) | 2021-05-21 | 2023-04-01 | 美商克迪科思股份有限公司 | 經工程化的甲硫胺酸γ解離酶變異體 |
| CA3227215A1 (en) | 2021-07-30 | 2023-02-02 | Trish Choudhary | Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| CA3227236A1 (en) | 2021-08-19 | 2023-02-23 | Trish Choudhary | Recombinant olivetolic acid cyclase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| JP2024539636A (ja) | 2021-10-15 | 2024-10-29 | コデクシス, インコーポレイテッド | 操作されたdnaポリメラーゼバリアント |
| WO2023069921A1 (en) | 2021-10-19 | 2023-04-27 | Epimeron Usa, Inc. | Recombinant thca synthase polypeptides engineered for enhanced biosynthesis of cannabinoids |
| WO2023077169A2 (en) | 2021-11-01 | 2023-05-04 | Codexis, Inc. | Engineered leucine decarboxylases |
| EP4490202A1 (en) | 2022-03-11 | 2025-01-15 | University of Rochester | Cyclopeptibodies and uses thereof |
| JP2025510621A (ja) | 2022-03-31 | 2025-04-15 | 青島清原化合物有限公司 | モノアミン酸化酵素及びその応用 |
| WO2023245171A1 (en) | 2022-06-17 | 2023-12-21 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof |
| WO2023245168A1 (en) | 2022-06-17 | 2023-12-21 | Synlogic Operating Company, Inc. | Bacteria engineered to treat diseases associated with bile acid metabolism and methods of use thereof |
| EP4543470A1 (en) | 2022-06-23 | 2025-04-30 | Synlogic Operating Company, Inc. | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof |
| EP4573553A1 (en) | 2022-08-15 | 2025-06-25 | ABSCI Corporation | Quantitative affinity activity specific cell enrichment |
| EP4649143A1 (en) | 2023-01-12 | 2025-11-19 | Novartis AG | Engineered ketoreductase polypeptides |
| WO2025061911A1 (en) | 2023-09-22 | 2025-03-27 | Glaxosmithkline Intellectual Property Development Limited | Methods of producing nucleotide triphosphates (ntps) |
| WO2025144700A1 (en) | 2023-12-27 | 2025-07-03 | Absci Corporation | Nanobody library screening using bacterial surface display |
| US20250297291A1 (en) | 2024-03-19 | 2025-09-25 | General Biological Corporation | Bio-based production of succinic acid using vibrio natriegens |
| WO2025235589A1 (en) | 2024-05-08 | 2025-11-13 | Codexis, Inc. | Dna polymerase variants |
| WO2025240660A1 (en) | 2024-05-15 | 2025-11-20 | Foresite Labs, Llc | Drug development and drug activity determination for coronary artery disease (cad) |
| WO2025242702A1 (en) | 2024-05-23 | 2025-11-27 | Glaxosmithkline Intellectual Property Development Limited | Enzymatic process for producing n-acetyl galactosamine clusters |
Family Cites Families (200)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US3996945A (en) * | 1975-04-07 | 1976-12-14 | Mcdowell James A | Extinguisher for cigarettes or cigars |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4351901A (en) * | 1980-03-24 | 1982-09-28 | Cetus Corporation | Method for single nucleotide alteration |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4695543A (en) * | 1982-03-23 | 1987-09-22 | Bristol-Myers Company | Alpha Interferon GX-1 |
| US5618697A (en) | 1982-12-10 | 1997-04-08 | Novo Nordisk A/S | Process for preparing a desired protein |
| US4994379A (en) | 1983-03-09 | 1991-02-19 | Cetus Corporation | Modified signal peptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5538868A (en) | 1984-02-08 | 1996-07-23 | Cetus Oncology Corporation | Recombinant ricin toxin fragments |
| US5422266A (en) * | 1984-12-31 | 1995-06-06 | University Of Georgia Research Foundation, Inc. | Recombinant DNA vectors capable of expressing apoaequorin |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5176995A (en) | 1985-03-28 | 1993-01-05 | Hoffmann-La Roche Inc. | Detection of viruses by amplification and hybridization |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| EP0316018A3 (en) * | 1985-03-29 | 1989-07-26 | Cetus Oncology Corporation | Modification of dna sequences |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE229046T1 (de) * | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| US4959312A (en) | 1985-05-31 | 1990-09-25 | The University Of Tennessee Research Corporation | Full spectrum mutagenesis |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DE3688920D1 (de) | 1985-07-03 | 1993-09-30 | Genencor Int | Hybride Polypeptide und Verfahren zu deren Herstellung. |
| US5866363A (en) | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| FI72765C (fi) | 1986-02-13 | 1987-07-10 | Valmet Oy | Utbredningsvals eller motsvarande foer vaevnaden i en pappersmaskin samt foerfarande foer framstaellning av denna. |
| DK311186D0 (da) | 1986-06-30 | 1986-06-30 | Novo Industri As | Enzymer |
| US5824469A (en) | 1986-07-17 | 1998-10-20 | University Of Washington | Method for producing novel DNA sequences with biological activity |
| US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
| US4994368A (en) | 1987-07-23 | 1991-02-19 | Syntex (U.S.A.) Inc. | Amplification method for polynucleotide assays |
| DK6488D0 (da) | 1988-01-07 | 1988-01-07 | Novo Industri As | Enzymer |
| WO1989006694A1 (en) * | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5206152A (en) * | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US4994366A (en) * | 1988-04-28 | 1991-02-19 | Jac Creative Foods, Inc. | Shrimp analog forming process |
| JPH03505966A (ja) * | 1988-07-14 | 1991-12-26 | ベイラー カレッジ オブ メディシン | 生物高分子の固相組立及び再構築方法 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FR2641793B1 (fr) | 1988-12-26 | 1993-10-01 | Setratech | Procede de recombinaison in vivo de sequences d'adn presentant des mesappariements de bases |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| DD282028A5 (de) | 1989-02-16 | 1990-08-29 | Akad Wissenschaften Ddr | Verfahren zur herstellung einer thermostabilen, hybriden bacillus-beta-1,3-1,4-glukanase |
| ATE143696T1 (de) * | 1989-02-28 | 1996-10-15 | Canon Kk | Partiell doppelsträngiges oligonukleotid und verfahren zu seiner bildung |
| DE3909710A1 (de) * | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur expression eines rekombinanten gens |
| US5043272A (en) | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
| US5106727A (en) | 1989-04-27 | 1992-04-21 | Life Technologies, Inc. | Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers |
| JPH0372882A (ja) | 1989-05-10 | 1991-03-28 | Eastman Kodak Co | 合成二本鎖dna配列の構築 |
| US5556750A (en) | 1989-05-12 | 1996-09-17 | Duke University | Methods and kits for fractionating a population of DNA molecules based on the presence or absence of a base-pair mismatch utilizing mismatch repair systems |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| DK169306B1 (da) | 1989-06-14 | 1994-10-10 | Af 18 Juni 1990 As | Middel til fjernelse eller inaktivering af uønskede komponenter i blod eller andre ekstracellulære legemsvæsker samt fremgangsmåde til fremstilling af dextran-O-carbonyl-benzo-18-crown-6 og af dextran-hydroxyethylbenzo-18-crown-6 |
| DK0405858T3 (da) | 1989-06-26 | 1995-09-04 | Lilly Co Eli | Kontrol af akkumulering af aberrante ekspressionsvektorer under fermenteringsprocedurer |
| US5240845A (en) * | 1989-07-11 | 1993-08-31 | Otsuka Pharmaceutical Factory, Ltd. | Mutated streptokinase proteins |
| US5045450A (en) * | 1989-07-13 | 1991-09-03 | Massachusetts Institute Of Technology | Determination of a mutational spectrum |
| IT1231157B (it) | 1989-07-20 | 1991-11-19 | Crc Ricerca Chim | Nuovi geni ibridi funzionali di bacillus thuringiensis ottenuti mediante ricombinazione in vivo. |
| US5514787A (en) * | 1989-07-21 | 1996-05-07 | Washington University | DNA sequences encoding human membrane cofactor protein (MCP) |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5023171A (en) | 1989-08-10 | 1991-06-11 | Mayo Foundation For Medical Education And Research | Method for gene splicing by overlap extension using the polymerase chain reaction |
| US5360726A (en) | 1989-09-12 | 1994-11-01 | Board Of Trustees Operating Michigan State University | Polypeptides enabling sorting of proteins to vacuoles in plants |
| US5030568A (en) * | 1989-09-29 | 1991-07-09 | Minnesota Mining And Manufacturing Company | Bioconversion of naphthalene monomers |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| WO1991007506A1 (en) | 1989-11-08 | 1991-05-30 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | A method of synthesizing double-stranded dna molecules |
| DE4000939A1 (de) * | 1990-01-15 | 1991-07-18 | Brem Gottfried Prof Dr Dr | Verfahren zur antikoerpergewinnung |
| US5427930A (en) | 1990-01-26 | 1995-06-27 | Abbott Laboratories | Amplification of target nucleic acids using gap filling ligase chain reaction |
| EP0439182B1 (en) | 1990-01-26 | 1996-04-24 | Abbott Laboratories | Improved method of amplifying target nucleic acids applicable to both polymerase and ligase chain reactions |
| JP4251406B2 (ja) | 1990-04-05 | 2009-04-08 | クレア,ロベルト | ウォーク―スルー突然変異誘発 |
| WO1991016427A1 (en) | 1990-04-24 | 1991-10-31 | Stratagene | Methods for phenotype creation from multiple gene populations |
| US5877402A (en) | 1990-05-01 | 1999-03-02 | Rutgers, The State University Of New Jersey | DNA constructs and methods for stably transforming plastids of multicellular plants and expressing recombinant proteins therein |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5851813A (en) | 1990-07-12 | 1998-12-22 | President And Fellows Of Harvard College | Primate lentivirus antigenic compositions |
| ATE176002T1 (de) * | 1990-07-24 | 1999-02-15 | Hoffmann La Roche | Verringerung von nicht spezifischer amplifikation während einer (in vitro) nukleinsäure amplifikation unter verwendung von modifizierten nukleinsäure basen |
| US5169764A (en) | 1990-08-08 | 1992-12-08 | Regeneron Pharmaceuticals, Inc. | Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras |
| DE69128898T2 (de) * | 1990-08-15 | 1998-05-28 | Therion Biolog Corp | Selbstständig zusammenfügende replikationsdefekte hybride viruspartikel |
| WO1992003461A1 (en) | 1990-08-24 | 1992-03-05 | Ixsys, Inc. | Methods of synthesizing oligonucleotides with random codons |
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| CA2049879A1 (en) | 1990-08-30 | 1992-03-01 | Keith C. Backman | Controlled initial target-dependent production of templates for ligase chain reaction |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| IL99553A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing oligonucleotides linked to expression elements,a kit for the preparation of vectors useful for the expression of a diverse population of random peptides and methods utilizing the same |
| US5871974A (en) | 1990-09-28 | 1999-02-16 | Ixsys Inc. | Surface expression libraries of heteromeric receptors |
| US5858725A (en) | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
| US5187083A (en) | 1990-11-13 | 1993-02-16 | Specialty Laboratories, Inc. | Rapid purification of DNA |
| US5234824A (en) | 1990-11-13 | 1993-08-10 | Specialty Laboratories, Inc. | Rapid purification of DNA |
| US5489523A (en) | 1990-12-03 | 1996-02-06 | Stratagene | Exonuclease-deficient thermostable Pyrococcus furiosus DNA polymerase I |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| AU9166691A (en) | 1990-12-20 | 1992-07-22 | Ixsys, Inc. | Optimization of binding proteins |
| US5795747A (en) | 1991-04-16 | 1998-08-18 | Evotec Biosystems Gmbh | Process for manufacturing new biopolymers |
| DE4112440C1 (enExample) | 1991-04-16 | 1992-10-22 | Diagen Institut Fuer Molekularbiologische Diagnostik Gmbh, 4000 Duesseldorf, De | |
| US5514568A (en) | 1991-04-26 | 1996-05-07 | Eli Lilly And Company | Enzymatic inverse polymerase chain reaction |
| US5512463A (en) | 1991-04-26 | 1996-04-30 | Eli Lilly And Company | Enzymatic inverse polymerase chain reaction library mutagenesis |
| DK0519338T3 (da) | 1991-06-20 | 1996-10-28 | Hoffmann La Roche | Forbedrede fremgangsmåder til nukleinsyreamplifikation |
| WO1993000103A1 (en) | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
| US5702931A (en) * | 1991-07-01 | 1997-12-30 | Berlex Laboratories, Inc. | Mutagenesis methods and compositions |
| US6071889A (en) | 1991-07-08 | 2000-06-06 | Neurospheres Holdings Ltd. | In vivo genetic modification of growth factor-responsive neural precursor cells |
| US5223408A (en) | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| US5279952A (en) | 1991-08-09 | 1994-01-18 | Board Of Regents, The University Of Texas System | PCR-based strategy of constructing chimeric DNA molecules |
| EP0773227A1 (en) | 1991-09-18 | 1997-05-14 | Affymax Technologies N.V. | Diverse collections of oligomers in use to prepare drugs, diagnostic reagents, pesticides or herbicides |
| ATE181571T1 (de) | 1991-09-23 | 1999-07-15 | Medical Res Council | Methoden zur herstellung humanisierter antikörper |
| US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5872215A (en) * | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| CA2127126A1 (en) | 1992-01-30 | 1993-08-05 | Helen M. Wilks | Chiral synthesis with modified enzymes |
| US5773267A (en) * | 1992-02-07 | 1998-06-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | D29 shuttle phasmids and uses thereof |
| GB9202796D0 (en) | 1992-02-11 | 1992-03-25 | Wellcome Found | Antiviral antibody |
| US5843643A (en) | 1992-02-21 | 1998-12-01 | Ratner; Paul L. | Site-specific transfection of eukaryotic cells using polypeptide-linked recombinant nucleic acid |
| CA2131389A1 (en) | 1992-03-02 | 1993-09-16 | John M. Maraganore | Thrombin receptor antagonists |
| WO1993018175A1 (en) * | 1992-03-10 | 1993-09-16 | Life Technologies, Inc. | Udg-facilitated mutagenesis |
| DE69333669T2 (de) | 1992-03-16 | 2006-03-09 | Wohlstadter, Jacob N. | Mutagenese und selektionsmethoden in den selben wirtszellen |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| DE69329641T2 (de) | 1992-03-31 | 2001-06-21 | Abbott Laboratories, Abbott Park | Verfahren zur mehrfachen ligase-kettenreaktion |
| US5316935A (en) | 1992-04-06 | 1994-05-31 | California Institute Of Technology | Subtilisin variants suitable for hydrolysis and synthesis in organic media |
| US5474896A (en) * | 1992-05-05 | 1995-12-12 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| JPH08503600A (ja) | 1992-05-29 | 1996-04-23 | アボツト・ラボラトリーズ | Rna配列で開始させるリガーゼ連鎖反応 |
| EP0606430A1 (en) | 1992-06-15 | 1994-07-20 | City Of Hope | Chimeric anti-cea antibody |
| WO1994001563A1 (en) | 1992-07-10 | 1994-01-20 | Energy Biosystems Corporation | Recombinant dna encoding a desulfurization biocatalyst |
| US6107062A (en) | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
| WO1994008047A1 (en) | 1992-09-25 | 1994-04-14 | Abbott Laboratories | Ligase chain reaction method for detecting small mutations |
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| JPH08505524A (ja) | 1992-11-10 | 1996-06-18 | イグジス, インコーポレイティッド | 溶液中で拘束された二次コンホメーションを有する可溶性ペプチド、およびその製造方法 |
| DE4239311C2 (de) | 1992-11-23 | 1996-04-18 | Guehring Joerg Dr | Bohrer, insbesondere Spitzbohrwerkzeug mit austauschbarem Schneideinsatz |
| WO1994012632A1 (en) * | 1992-11-27 | 1994-06-09 | University College London | Improvements in nucleic acid synthesis by pcr |
| US5360728A (en) | 1992-12-01 | 1994-11-01 | Woods Hole Oceanographic Institution (W.H.O.I.) | Modified apoaequorin having increased bioluminescent activity |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5541311A (en) | 1992-12-07 | 1996-07-30 | Third Wave Technologies, Inc. | Nucleic acid encoding synthesis-deficient thermostable DNA polymerase |
| JP2879303B2 (ja) * | 1993-01-14 | 1999-04-05 | 佑 本庶 | cDNAライブラリーの作製方法、および新規なポリペプチドとそれをコードするDNA |
| US5571708A (en) | 1993-04-19 | 1996-11-05 | Bristol-Myers Squibb Company | Thrombin-activatable plasminogen activator |
| US5501962A (en) | 1993-06-21 | 1996-03-26 | G. D. Searle & Co. | Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same |
| IT1264712B1 (it) | 1993-07-13 | 1996-10-04 | Eniricerche Spa | Metodo di sintesi biologica di peptidi |
| US5547859A (en) | 1993-08-02 | 1996-08-20 | Goodman; Myron F. | Chain-terminating nucleotides for DNA sequencing methods |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| IL107268A0 (en) | 1993-10-12 | 1994-01-25 | Yeda Res & Dev | Molecules influencing the shedding of the tnf receptor, their preparation and their use |
| JPH09507121A (ja) | 1993-10-26 | 1997-07-22 | アフィマックス テクノロジーズ ナームロゼ ベノートスハップ | 生物学的チップ上の核酸プローブアレー |
| US6027877A (en) | 1993-11-04 | 2000-02-22 | Gene Check, Inc. | Use of immobilized mismatch binding protein for detection of mutations and polymorphisms, purification of amplified DNA samples and allele identification |
| US5556772A (en) | 1993-12-08 | 1996-09-17 | Stratagene | Polymerase compositions and uses thereof |
| DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
| US6406855B1 (en) * | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6395547B1 (en) * | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6117679A (en) * | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5521077A (en) | 1994-04-28 | 1996-05-28 | The Leland Stanford Junior University | Method of generating multiple protein variants and populations of protein variants prepared thereby |
| US5728821A (en) * | 1994-08-04 | 1998-03-17 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| WO1996017056A1 (en) * | 1994-12-02 | 1996-06-06 | Institut Pasteur | Hypermutagenesis |
| US5514588A (en) | 1994-12-13 | 1996-05-07 | Exxon Research And Engineering Company | Surfactant-nutrients for bioremediation of hydrocarbon contaminated soils and water |
| US5629179A (en) | 1995-03-17 | 1997-05-13 | Novagen, Inc. | Method and kit for making CDNA library |
| WO1996034112A1 (en) | 1995-04-24 | 1996-10-31 | Chromaxome Corp. | Methods for generating and screening novel metabolic pathways |
| US5885813A (en) | 1995-05-31 | 1999-03-23 | Amersham Life Science, Inc. | Thermostable DNA polymerases |
| US5667974A (en) | 1995-06-07 | 1997-09-16 | Abbott Laboratories | Method for detecting nucleic acid sequences using competitive amplification |
| CA2151183C (en) * | 1995-06-07 | 2005-05-17 | Slawomir Jonasz | Composite compression molded article, composition therefor and process for manufacture thereof, and use |
| US6030779A (en) | 1995-07-18 | 2000-02-29 | Diversa Corporation | Screening for novel bioactivities |
| US6168919B1 (en) | 1996-07-17 | 2001-01-02 | Diversa Corporation | Screening methods for enzymes and enzyme kits |
| US5958672A (en) | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
| US6057103A (en) | 1995-07-18 | 2000-05-02 | Diversa Corporation | Screening for novel bioactivities |
| US6004788A (en) | 1995-07-18 | 1999-12-21 | Diversa Corporation | Enzyme kits and libraries |
| JP4156666B2 (ja) | 1995-08-11 | 2008-09-24 | ノボザイムス アクティーゼルスカブ | ポリペプチド変異体を調整するための方法 |
| US5962258A (en) | 1995-08-23 | 1999-10-05 | Diversa Corporation | Carboxymethyl cellulase fromthermotoga maritima |
| US6051409A (en) | 1995-09-25 | 2000-04-18 | Novartis Finance Corporation | Method for achieving integration of exogenous DNA delivered by non-biological means to plant cells |
| US5756316A (en) | 1995-11-02 | 1998-05-26 | Genencor International, Inc. | Molecular cloning by multimerization of plasmids |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| JP2000501606A (ja) | 1995-12-07 | 2000-02-15 | リコンビナント バイオカタリシス,インコーポレーテッド | 酵素活性をスクリーニングする方法 |
| US6352842B1 (en) | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
| US6361974B1 (en) | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| US5939250A (en) | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis |
| US20030215798A1 (en) | 1997-06-16 | 2003-11-20 | Diversa Corporation | High throughput fluorescence-based screening for novel enzymes |
| US6358709B1 (en) | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
| US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
| EP0873398B1 (en) | 1996-01-10 | 2005-04-20 | Novozymes A/S | A method for in vivo production of a mutant library in cells |
| US5871969A (en) * | 1996-02-12 | 1999-02-16 | Human Genome Sciences, Inc. | Nucleic acids encoding human neuronal attachment factor-1 |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| US5783431A (en) | 1996-04-24 | 1998-07-21 | Chromaxome Corporation | Methods for generating and screening novel metabolic pathways |
| JP2000512142A (ja) * | 1996-06-07 | 2000-09-19 | マサチューセッツ インスティチュート オブ テクノロジー | プログラムされた連続的変異誘発 |
| US5763239A (en) | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
| US6093873A (en) | 1996-08-19 | 2000-07-25 | Institut National De La Sante Et De La Recherche Medicale | Genetically engineered mice containing alterations in the gene encoding RXR |
| EP0964922A4 (en) | 1996-09-27 | 2000-10-25 | Maxygen Inc | METHOD FOR OPTIMIZING GENE THERAPY BY REPEATING SEQUENCE MIXING AND SELECTION |
| EP0963434A4 (en) | 1996-09-27 | 2000-10-25 | Maxygen Inc | METHODS FOR OPTIMIZING GENE THERAPY THROUGH RECURRENT SEARCHING AND SEQUENCE SELECTION |
| CN1208456C (zh) | 1996-12-20 | 2005-06-29 | 诺维信公司 | 体内重组 |
| US6326204B1 (en) * | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US6159687A (en) | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods for generating recombined polynucleotides |
| NZ337900A (en) | 1997-03-18 | 2001-05-25 | Novo Nordisk As | DNA shuffling for randomised heterologous and homogenous 3' and 5' primers for construction of DNA libraries for generation of more desirable mutants |
| DK1015575T3 (da) | 1997-03-18 | 2010-08-23 | Novozymes As | Shuffling af heterologe DNA-sekvenser |
| EP0996718B1 (en) | 1997-03-18 | 2008-12-24 | Novozymes A/S | Method for constructing a library using dna shuffling |
| US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
| US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| US6051049A (en) | 1997-05-29 | 2000-04-18 | Exothermic Distribution Corporation | Utilization of strontium aluminate in steelmaking |
| WO1999029902A1 (en) | 1997-12-08 | 1999-06-17 | California Institute Of Technology | Method for creating polynucleotide and polypeptide sequences |
| US6087341A (en) | 1998-02-12 | 2000-07-11 | The Board Of Trustees Of The Leland Standford Junior University | Introduction of nucleic acid into skin cells by topical application |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| US6376246B1 (en) * | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6436675B1 (en) * | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| EP1152058A1 (en) * | 2000-05-03 | 2001-11-07 | Institut Curie | Methods and compositions for effecting homologous recombination |
| US6355160B1 (en) | 2000-07-21 | 2002-03-12 | Cecil A. Wiseman | Gray-water recycling system |
-
1996
- 1996-12-18 US US08/769,062 patent/US6335160B1/en not_active Expired - Lifetime
-
1997
- 1997-12-17 AT AT01202350T patent/ATE481480T1/de active
- 1997-12-17 ES ES01202350T patent/ES2351673T3/es not_active Expired - Lifetime
- 1997-12-17 EP EP10075154A patent/EP2202308B1/en not_active Expired - Lifetime
- 1997-12-17 IL IL13019097A patent/IL130190A0/xx unknown
- 1997-12-17 KR KR1019997005569A patent/KR20000069591A/ko not_active Withdrawn
- 1997-12-17 DK DK10075154.4T patent/DK2202308T3/da active
- 1997-12-17 DK DK01202350.3T patent/DK1149905T3/da active
- 1997-12-17 WO PCT/US1997/024239 patent/WO1998027230A1/en not_active Ceased
- 1997-12-17 CA CA2274319A patent/CA2274319C/en not_active Expired - Fee Related
- 1997-12-17 DE DE69739996T patent/DE69739996D1/de not_active Expired - Lifetime
- 1997-12-17 JP JP52805498A patent/JP5008784B2/ja not_active Expired - Fee Related
- 1997-12-17 EP EP97953571A patent/EP0946755A4/en not_active Withdrawn
- 1997-12-17 EP EP01202349A patent/EP1149904A1/en not_active Withdrawn
- 1997-12-17 EP EP02001412A patent/EP1231269A1/en not_active Withdrawn
- 1997-12-17 EP EP01202350A patent/EP1149905B1/en not_active Expired - Lifetime
- 1997-12-17 AU AU57292/98A patent/AU732146B2/en not_active Withdrawn - After Issue
- 1997-12-17 CA CA002589337A patent/CA2589337A1/en not_active Abandoned
-
1999
- 1999-06-24 US US09/339,926 patent/US6653072B1/en not_active Expired - Fee Related
- 1999-06-24 US US09/339,913 patent/US6303344B1/en not_active Expired - Lifetime
- 1999-06-24 US US09/344,002 patent/US6355484B1/en not_active Expired - Lifetime
- 1999-06-25 US US09/339,904 patent/US6319713B1/en not_active Expired - Lifetime
-
2000
- 2000-04-27 US US09/559,565 patent/US6455253B1/en not_active Expired - Fee Related
- 2000-04-27 US US09/559,671 patent/US6613514B2/en not_active Expired - Fee Related
- 2000-10-20 US US09/693,350 patent/US6579678B1/en not_active Expired - Fee Related
- 2000-10-20 US US09/693,389 patent/US6586182B1/en not_active Expired - Fee Related
-
2001
- 2001-09-12 US US09/954,692 patent/US6946296B2/en not_active Expired - Fee Related
-
2003
- 2003-08-22 US US10/646,221 patent/US7534564B2/en not_active Expired - Fee Related
- 2003-09-22 US US10/667,868 patent/US20050059109A1/en not_active Abandoned
- 2003-09-22 US US10/667,772 patent/US20040214277A1/en not_active Abandoned
-
2005
- 2005-05-24 US US11/136,115 patent/US20060166225A1/en not_active Abandoned
- 2005-08-05 US US11/198,765 patent/US20060084091A1/en not_active Abandoned
- 2005-11-23 US US11/286,271 patent/US20060223143A1/en not_active Abandoned
-
2006
- 2006-09-06 US US11/515,879 patent/US20070031878A1/en not_active Abandoned
-
2008
- 2008-02-05 US US12/069,011 patent/US7776598B2/en not_active Expired - Fee Related
- 2008-12-01 JP JP2008306897A patent/JP2009089710A/ja not_active Withdrawn
-
2009
- 2009-09-11 US US12/557,983 patent/US20110053781A1/en not_active Abandoned
-
2011
- 2011-09-01 US US13/224,145 patent/US20120015820A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2274319C (en) | Methods and compositions for polypeptide engineering | |
| US6406855B1 (en) | Methods and compositions for polypeptide engineering | |
| US20070009930A1 (en) | Methods and compositions for polypeptide engineering | |
| AU2011202018B2 (en) | Methods and compositions for polypeptide engineering | |
| AU2004210610A1 (en) | Methods and compositions for polypeptide engineering | |
| AU2761602A (en) | Methods and compositions for polypeptide engineering | |
| MXPA99005653A (en) | Methods and compositions for polypeptide engineering |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20151217 |